o
|
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
|
x
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
o
|
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Securities registered or to be registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Name of each exchange on which registered
|
American Depositary Shares,
each representing ten Ordinary Shares
|
NASDAQ Capital Market
|
Securities registered or to be registered pursuant to Section 12(g) of the Act:
None
|
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:
None
|
U.S. GAAP
o
|
International Financial Reporting Standards as issued by the International Accounting Standards Board
x
|
Other
o
|
PART I | 5 | |
5
|
||
5
|
||
5
|
||
A.
|
Selected Consolidated Financial Data
|
5
|
B.
|
Capitalization and Indebtedness
|
6
|
C.
|
Reasons for the Offer and Use of Proceeds
|
6
|
D.
|
Risk Factors
|
7
|
20
|
||
A.
|
History and Development of the Company
|
20
|
B.
|
Business Overview
|
21
|
C.
|
Organizational Structure
|
36
|
D.
|
Property, Plants and Equipment
|
36
|
36
|
||
36
|
||
A.
|
Operating Results
|
36
|
B.
|
Liquidity and Capital Resources
|
44
|
C.
|
Research and Development, Patents and Licenses
|
48
|
D.
|
Trend Information
|
48
|
E.
|
Off-Balance Sheet Arrangements
|
49
|
F.
|
Tabular Disclosure of Contractual Obligations
|
49
|
49
|
||
A.
|
Directors and Senior Management
|
49
|
B.
|
Compensation
|
52
|
C.
|
Board Practices
|
54
|
D.
|
Employees
|
57
|
E.
|
Share Ownership
|
57
|
61
|
||
A.
|
Major Shareholders
|
61
|
B.
|
Related Party Transactions
|
61
|
C.
|
Interests of Experts and Counsel
|
61
|
61
|
||
A.
|
Financial Statements and Other Financial Information
|
62
|
B.
|
Significant Changes
|
62
|
62
|
||
A.
|
Offer and Listing Details
|
62
|
B.
|
Plan of Distribution
|
63
|
C.
|
Markets
|
63
|
D.
|
Selling Shareholders
|
64
|
E.
|
Dilution
|
64
|
F.
|
Expenses of the Issue
|
64
|
64
|
||
A.
|
Share Capital
|
64
|
B.
|
Memorandum and Articles of Association
|
64
|
C.
|
Material Contracts
|
66
|
D.
|
Exchange Controls
|
67
|
E.
|
Taxation
|
68
|
F.
|
Dividends and Paying Agents
|
74
|
G.
|
Statement by Experts
|
74
|
H.
|
Documents on Display
|
74
|
I.
|
Subsidiary Information
|
75
|
75
|
||
75
|
|
77 | |
77
|
||
77
|
||
77
|
||
78
|
||
78
|
||
78
|
||
78
|
||
79
|
||
79
|
||
79
|
||
79
|
||
79
|
||
79
|
||
79
|
||
80
|
||
|
82 |
ITEM 1.
|
IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
|
ITEM 2.
|
OFFER STATISTICS AND EXPECTED TIMETABLE
|
ITEM 3.
|
KEY INFORMATION
|
A.
|
Selected Consolidated Financial Data
|
Statement of Comprehensive Income:
|
||||||||||||||||||||
Year Ended June 30,
|
||||||||||||||||||||
2015
|
2014
|
2013
|
2012
|
2011
|
||||||||||||||||
(in A$, except loss per share and number of shares)
|
||||||||||||||||||||
Revenue from continuing operations
|
176,842 | 363,775 | 150,867 | 186,664 | 156,135 | |||||||||||||||
Other income
|
6,317,438 | 7,845,396 | 4,488,526 | 2,340,851 | 6,785 | |||||||||||||||
Research and development expenses
|
(12,298,167 | ) | (14,908,098 | ) | (8,203,822 | ) | (4,252,002 | ) | (3,498,035 | ) | ||||||||||
Corporate personnel expenses
|
(2,344,337 | ) | (2,059,642 | ) | (2,298,426 | ) | (1,835,279 | ) | (1,225,754 | ) | ||||||||||
Intellectual property expenses
|
(257,299 | ) | (477,079 | ) | (294,894 | ) | (261,706 | ) | (399,237 | ) | ||||||||||
Auditor and accounting expenses
|
(416,271 | ) | (342,609 | ) | (166,086 | ) | (153,597 | ) | (157,436 | ) | ||||||||||
Travel expenses
|
(125,532 | ) | (421,013 | ) | (131,710 | ) | (91,624 | ) | (159,971 | ) | ||||||||||
Public relations and marketing expenses
|
(87,851 | ) | (358,597 | ) | (136,186 | ) | (124,970 | ) | (110,646 | ) | ||||||||||
Depreciation expenses
|
(31,587 | ) | (22,384 | ) | (23,130 | ) | (19,621 | ) | (31,577 | ) | ||||||||||
Other expenses
|
(1,626,076 | ) | (2,142,179 | ) | (1,169,407 | ) | (1,095,739 | ) | (853,523 | ) | ||||||||||
Interest expense – ADDF (see below)
|
- | (29,978 | ) | (17,676 | ) | (11,544 | ) | (3,758 | ) | |||||||||||
Foreign exchange gain (loss)
|
4,721,449 | (746,593 | ) | 140,761 | 45,959 | (145,377 | ) | |||||||||||||
Gain (loss) on fair value of financial liabilities
|
86,322 | (30,238 | ) | (126,059 | ) | 33,139 | (8,791 | ) | ||||||||||||
Net loss
|
(5,885,069 | ) | (13,329,239 | ) | (7,787,242 | ) | (5,239,469 | ) | (6,431,185 | ) | ||||||||||
Loss per share (cents per share) – basic and diluted
|
(1.17 | ) | (3.11 | ) | (2.30 | ) | (1.82 | ) | (2.60 | ) | ||||||||||
Weighted average number of ordinary shares outstanding - basic and diluted
|
502,714,982 | 428,047,123 | 338,700,006 | 287,765,812 | 247,578,570 |
Balance Sheet Data
|
||||||||||||||||||||
As at June 30,
|
||||||||||||||||||||
2015
|
2014
|
2013
|
2012
|
2011
|
||||||||||||||||
(in A$ )
|
||||||||||||||||||||
Cash and cash equivalents
|
34,909,574 | 34,167,018 | 13,346,760 | 5,636,469 | 8,838,245 | |||||||||||||||
Working capital
|
39,025,487 | 37,597,770 | 13,883,965 | 5,544,497 | 6,856,842 | |||||||||||||||
Total assets
|
41,834,382 | 41,640,855 | 17,073,821 | 7,341,868 | 9,010,952 | |||||||||||||||
Net assets
|
39,113,264 | 37,686,287 | 13,974,713 | 5,623,447 | 6,931,202 | |||||||||||||||
Issued capital
|
146,895,714 | 140,009,415 | 101,379,111 | 86,134,077 | 82,340,819 | |||||||||||||||
Share based payment reserves
|
9,363,181 | 8,937,434 | 10,526,925 | 9,633,451 | 9,494,995 | |||||||||||||||
Accumulated deficit during development stage
|
(117,145,631 | ) | (111,260,562 | ) | (97,931,323 | ) | (90,144,081 | ) | (84,904,612 | ) | ||||||||||
Total equity
|
39,113,264 | 37,686,287 | 13,974,713 | 5,623,447 | 6,931,202 |
Year
Ended June 30,
|
At Period End
|
Average Rate
|
High
|
Low
|
||||||||||||
2011
|
1.0597 | 0.9894 | 1.1011 | 0.8323 | ||||||||||||
2012
|
1.0161 | 1.0327 | 1.1080 | 0.9387 | ||||||||||||
2013
|
0.9146 | 1.0273 | 1.0624 | 0.9112 | ||||||||||||
2014
|
0.9439 | 0.9183 | 0.9757 | 0.8659 | ||||||||||||
2015
|
0.7655 | 0.8369 | 0.9457 | 0.7580 |
Month
|
High
|
Low
|
||||||
April 2015
|
0.8011 | 0.7580 | ||||||
May 2015
|
0.8103 | 0.7637 | ||||||
June 2015
|
0.7783 | 0.7618 | ||||||
July 2015
|
0.7690 | 0.7277 | ||||||
August 2015 (through August 24)
|
0.7417 | 0.7288 |
B.
|
Capitalization and Indebtedness
|
C.
|
Reasons for the Offer and Use of Proceeds
|
D.
|
Risk Factors
|
|
·
|
the continued progress of our research and development programs;
|
|
·
|
the timing, scope, results and costs of pre-clinical studies and clinical trials;
|
|
·
|
the cost, timing and outcome of regulatory submissions and approvals;
|
|
·
|
determinations as to the commercial potential of our product candidates;
|
|
·
|
our ability to successfully expand our contract manufacturing services;
|
|
·
|
our ability to establish and maintain collaborative arrangements; and
|
|
·
|
the status and timing of competitive developments.
|
|
·
|
government or regulatory delays, including delays in obtaining approvals from applicable hospital ethics committees and internal review boards;
|
|
·
|
slower than expected patient enrollment;
|
|
·
|
our inability to manufacture sufficient quantities of our new proprietary compound or our other product candidates or matching controls;
|
|
·
|
unforeseen safety issues; or
|
|
·
|
lack of efficacy or unacceptable toxicity during the clinical trials or non-clinical studies.
|
|
·
|
the receipt and timing of regulatory approvals for the uses that we are studying;
|
|
·
|
the establishment and demonstration to the medical community of the safety, clinical efficacy or cost-effectiveness of our product candidates and their potential advantages over existing therapeutics and technologies; and
|
|
·
|
the pricing and reimbursement policies of governments and third-party payors.
|
|
·
|
obtain and maintain patents to protect our own products and technologies;
|
|
·
|
obtain orphan designation for our products and technologies;
|
|
·
|
obtain licenses to the patented technologies of third parties;
|
|
·
|
operate without infringing on the proprietary rights of third parties; and
|
|
·
|
protect our trade secrets, know-how and other confidential information.
|
|
·
|
Others may be able to make products that are similar to ours but that are not covered by the claims of the patents that we own.
|
|
·
|
Others may independently develop similar or alternative technologies or otherwise circumvent any of our technologies without infringing our intellectual property rights.
|
|
·
|
We or any of our collaboration partners might not have been the first to conceive and reduce to practice the inventions covered by the patents or patent applications that we own, license or will own or license.
|
|
·
|
We or any of our collaboration partners might not have been the first to file patent applications covering certain of the patents or patent applications that we or they own or have obtained a license, or will own or will have obtained a license.
|
|
·
|
It is possible that our pending patent applications will not lead to issued patents.
|
|
·
|
Issued patents that we own may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors.
|
|
·
|
Our competitors might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets.
|
|
·
|
The patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business.
|
|
·
|
Compulsory licensing provisions of certain governments to patented technologies that are deemed necessary for the government to access.
|
|
·
|
the results of pre-clinical testing and clinical trials by us and our competitors;
|
|
·
|
developments concerning research and development, manufacturing, and marketing alliances or collaborations by us and our competitors;
|
|
·
|
announcements of technological innovations or new commercial products by us and our competitors;
|
|
·
|
determinations regarding our patent applications, patents and those of others;
|
|
·
|
publicity regarding actual or potential results relating to medicinal products under development by us and our competitors;
|
|
·
|
proposed governmental regulations and developments in Australia, the United States and elsewhere;
|
|
·
|
litigation;
|
|
·
|
economic and other external factors; and
|
|
·
|
period-to-period fluctuations in our operating results.
|
ITEM 4.
|
INFORMATIO
N
ON THE COMPANY
|
A.
|
History and Development of the Company
|
B.
|
Business Overview
|
|
·
|
The Massachusetts General Hospital, Genetics and Aging Unit in Boston. Massachusetts General Hospital is the largest teaching hospital for Harvard Medical School;
|
|
·
|
The University of Melbourne, Department of Pathology; and
|
|
·
|
The Florey Institute of Neuroscience and Mental Health in Melbourne.
|
|
●
|
Significantly improved motor function and coordination as tested by the ability of MSA mice to remain on a rotating rod. Indeed this improvement has been sustained for five months. A reduction in the accumulation of the insoluble forms of α-synuclein.
|
|
●
|
In TgA53T, a generic model of synucleinopathy, to investigate Dementia with Lewy Bodies, animals treated with PBT434 exhibited significantly increased numbers of
s.nigra
neurons and a significant reduction in insoluble α-synuclein and incidence of clasping b
ehaviour. Cognition evaluated using the Y-Maze is also significantly improved.
|
|
●
|
In mutant overexpressing tau mice, rTg4510, PBT434 has demonstrated highly significant improvement in the Y-maze cognitive assessment. A significant reduction in the number of abnormal tau deposits in the hippocampus of 12 month old mice.
|
|
(i)
|
In November 2014, we achieved Allowance of patent claims in the United States covering the use of PBT2 for the treatment of Alzheimer’s disease. These claims provide a second level of protection, in addition to the successfully granted composition of matter claims to PBT2 in a related application.
|
|
(ii)
|
In October 2014, we filed a further Continuation application in the United States, with claims seeking coverage of the use of 8-hydroxyquinoline compounds for the treatment of Huntington’s disease. This case is currently in active prosecution with the USPTO.
|
|
(iii)
|
In October 2014, we filed a second Continuation application in the United States, with claims seeking coverage of the use of 8-hydroxyquinoline compounds, other than PBT2 for the treatment of Alzheimer’s disease. This case is currently in active prosecution with the USPTO.
|
|
(iv)
|
In April 2015, we received Notice of Grant from the Israeli Patent Office for our key patent protecting PBT519. The patent, which is entitled, ‘Method of treatment and prophylaxis and agents useful for same’ covers the composition of matter of selected pyridopyrimidine compounds, including PBT519. We have also Validated the European patent of this case in 16 major jurisdictions.
|
|
(v)
|
In April 2015, we received Notice of Grant from the Japanese and United States patent offices in relation to the patent family entitled ‘Quinazolinone compounds’, which covers selected novel chemical drug candidates related to PBT434 and their uses for neurological conditions, particularly Parkinson’s disease.
|
|
(vi)
|
In March 2015, we filed two Australian provisional patent applications directed to novel methods of synthesising compounds including the candidate PBT434 and compounds of similar structure. These patents are titled ‘A method of the production of 2-substituted-3H-quinazolin-4-ones-I’ and ‘A method of the production of 2-substituted-3H-quinazolin-4-ones-II‘.
|
|
(vii)
|
The patent family cases entitled ‘Compounds for Therapy and Diagnosis’ continues to be prosecuted in Canada and Europe. This case includes composition of matter claims to novel non-MPAC metallocomplex compounds that are designed to treat Alzheimer’s disease by binding to the metal binding site of Abeta in the brain. The case also covers the use of these metallocomplexes as imaging agents for Alzheimer’s disease.
|
|
(viii)
|
An Australian provisional patent application entitled ‘Processes for the preparation of an 8-Hydroxyquinoline derivative’ has been re-filed in January 2015 to cover alternative synthetic routes to selected 8-Hydroxyquinolines.
|
PATENT
|
STATUS
|
INVENTION
|
“Beta amyloid peptide inhibitors”
Filed: July 21, 2000
Applicant: Biomolecular Research Institute and University of Melbourne
Assigned to Prana.
|
Patents have been granted in the USA, Canada and Australia.
|
The invention encompasses claims to specific classes of metallocomplex agents capable of inhibiting binding of specified metal ions to the N-terminus of beta-amyloid and the use of these agents in the treatment of amyloid related conditions including Alzheimer’s Disease.
|
“Neurotoxic Oligomers”
Filed: June 28, 2000
Applicants: Prana and The General Hospital Corporation
|
Patents have been granted in Australia, New Zealand, Canada, China and the USA (2). A case has been Granted in Europe and has been validated in separate countries.
|
The invention is directed to an immunotherapy strategy using or targeting tyrosine cross-linked protein aggregates. The approach may be used in the treatment of Alzheimer’s Disease and other amyloid related conditions.
|
“8-Hydroxyquinoline Derivatives”
Filed: July 16, 2003
Applicant: Prana
|
Patents in Europe, the USA, New Zealand, Canada, Japan, Russia, Singapore, South Korea, Australia, Israel, China, Mexico and South Africa have been Granted. A patent in Hong Kong has been registered. Applications in India and Brazil are under examination. Two continuation applications in the USA are also under examination.
|
The invention is directed to chemical scaffolds of the 8-Hydroxyquinoline MPAC class and their utility in the treatment of neurological conditions.
|
“Neurologically-Active Compounds”
Filed: October 3 , 2003
Applicant: Prana
|
Patents in the USA, New Zealand, Canada, Japan, Mexico, India, Australia, China, South Korea, Japan, Israel, South Africa and Singapore have been granted. A case has been granted in Europe and has been validated in separate countries. An application in Brazil is under examination. A patent in Hong Kong has been registered.
|
The invention is directed to alternative MPAC chemical structures and their utility in the treatment of neurological conditions.
|
C.
|
Organizational Structure
|
D.
|
Property, Plants and Equipment
|
ITEM 5.
|
OPERATING AND FINANCIAL REVIEW AND PROSPECTS
|
A.
|
Operating Results
|
|
·
|
the technical feasibility of completing the intangible asset so that it will be available for use or sale;
|
|
·
|
the intention to complete the intangible asset and use or sell it;
|
|
·
|
the ability to use or sell the intangible asset;
|
|
·
|
how the intangible asset will generate probable future economic benefits;
|
|
·
|
the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and
|
|
·
|
the ability to measure reliably the expenditure attributable to the intangible asset during its development.
|
·
Furniture and fittings:
|
5-33%
|
·
Computer equipment:
|
33%
|
·
Laboratory equipment:
|
10-33%
|
·
Leasehold improvements:
|
33%
|
Pronouncement
|
Title (Issue date)
|
Effective date
|
Amendment to IFRS 11
|
Joint arrangements on acquisition of an interest in a joint operation
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
Amendment to IAS 16 and IAS 41
|
Property, plant and equipment and Agriculture, regarding bearer plants
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
Amendment to IAS 16 and IAS 38
|
Property, plant and equipment and Intangible assets on depreciation and amortization
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
IFRS 14
|
Regulatory deferral accounts
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
Pronouncement
|
Title (Issue date)
|
Effective date
|
Amendments to IAS 27
|
Separate financial statements on the equity method
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
Amendments to IFRS 10 and IAS 28
|
Consolidated financial statements and Investments in associates and joint ventures
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
Annual improvements 2014 to IFRS 5
|
Non-current assets held for sale and discontinued operations regarding methods of disposal
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
Annual improvements 2014 to IFRS 7
|
Financial instruments: Disclosures, (with consequential amendments to IFRS 1) regarding servicing contracts
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
Annual improvements 2014 to IAS 19
|
Employee benefits regarding discount rates
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
Annual improvements 2014 to IAS 34
|
Interim financial reporting regarding disclosure of information
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
Amendment to IAS 1
|
Presentation of financial statements on the disclosure initiative
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
Amendment to IFRS 10 and IAS 28
|
Investment entities applying the consolidation exception
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
IFRS 15
|
Revenue from contracts with customers
|
Annual periods beginning on or after January 1, 2017
Earlier application is permitted.
|
IFRS 9
|
Financial instruments
|
Annual periods beginning on or after January 1, 2018
Earlier application is permitted.
|
B.
|
Liquidity and Capital Resources
|
·
|
Core activities, which are experimental activities whose outcome cannot be known or determined in advance, but can only be determined by applying a systematic progression of work;
|
·
|
Core activities conducted for the purpose of generating new knowledge (including new knowledge in the form of new or improved processes and materials); or
|
·
|
Supporting activities that are directly related and designed to support the above).
|
Year ended June 30,
|
||||||||||||
2015
|
2014
|
2013
|
||||||||||
(A$) | ||||||||||||
Net cash used in operating activities
|
(10,871,074 | ) | (13,536,223 | ) | (7,951,254 | ) | ||||||
Net cash used in investing activities
|
(182,834 | ) | (23,048 | ) | (28,151 | ) | ||||||
Net cash provided by financing activities
|
6,843,211 | 34,960,792 | 15,582,031 | |||||||||
Net increase (decrease) in cash and cash equivalents
|
(4,210,697 | ) | 21,401,521 | 7,602,626 | ||||||||
Cash and cash equivalents at beginning of period
|
34,167,018 | 13,346,760 | 5,636,469 | |||||||||
Exchange rate adjustments on cash held in foreign currencies
|
4,953,253 | (581,263 | ) | 107,665 | ||||||||
Cash and cash equivalents at end of period
|
34,909,574 | 34,167,018 | 13,346,760 |
C.
|
Research and Development, Patents and Licenses
|
D.
|
Trend Information
|
E.
|
Off-Balance Sheet Arrangements
|
F.
|
Tabular Disclosure of Contractual Obligations
|
Contractual Obligations
|
Payments due by period
|
|||||||||||||||||||
Total
|
less than 1 year
|
1-3 years
|
3-5
Years
|
more than
5 years
|
||||||||||||||||
Operating lease obligations
|
167,047 | 134,272 | 32,776 | - | - | |||||||||||||||
Total
|
167,047 | 134,272 | 32,776 | - | - |
ITEM 6.
|
DIRECTORS
,
SENIOR MANAGEMENT AND EMPLOYEES
|
A.
|
Directors and Senior Management
|
Name
|
Age
|
Position
|
||
Geoffrey P. Kempler
|
60
|
Chairman of the Board of Directors and Chief Executive Officer
|
||
Kathryn Andrews
|
48
|
Chief Financial Officer
|
||
Phillip A. Hains
|
55
|
Company Secretary
|
||
Dianne M. Angus
|
55
|
Chief Operating Officer
|
||
Peter A. Marks(1)
|
59
|
Director
|
||
Brian D. Meltzer(1)(2)(3)
|
61
|
Director
|
||
George W. Mihaly(1)(2)(3)
|
62
|
Director
|
||
Lawrence B. Gozlan(3)
|
36
|
Director
|
||
Ira Shoulson
|
69
|
Director
|
B.
|
Compensation
|
Salaries, fees,
commissions,
bonuses and other
|
Pension, retirement and other similar
benefits
|
|||||||
Geoffrey P. Kempler (1)
|
$ | A556,465 | -- | |||||
Phillip A. Hains (3)
|
$ | A100,000 | -- | |||||
Dianne M. Angus (2)
|
$ | A518,401 | -- | |||||
Kathryn Andrews (5)
|
$ | A88,857 | -- | |||||
Peter A. Marks
|
$ | A60,000 | -- | |||||
Brian D. Meltzer
|
$ | A85,000 | -- | |||||
George W. Mihaly
|
$ | A75,000 | -- | |||||
Lawrence B. Gozlan
|
$ | A50,000 | -- | |||||
Ira Shoulson (4)
|
$ | A250,648 | -- | |||||
Richard Revelins (6)
|
$ | A39,926 | -- |
|
(1)
|
During the 2015 fiscal year, Mr. Kempler received a A$100,000 incentive bonus which he was awarded in 2012.
|
|
(2)
|
During the 2015 fiscal year, Ms. Angus received options to purchase 1,000,000 ordinary shares, which are exercisable which are exercisable for A$0.34 per share on or before October 2, 2018, as remuneration for her services.
|
|
(3)
|
Mr. Hains retired from his appointment as Acting Chief Financial Officer and was appointed as Company Secretary on November 4, 2014.
|
|
(4)
|
Prof. Ira Shoulson provides consulting services to the company in a separate capacity to his position as Non-Executive Director. Total cash compensation of $205,426 was paid to Prof. Ira Shoulson during the 2015 fiscal year in his capacity as a consultant to the Company.
|
|
(5)
|
Ms. Andrews was appointed as Chief Financial Officer on November 4, 2014.
|
|
(6)
|
Mr. Revelins retired from his position as Company Secretary and Chief Financial Officer on November 4, 2014.
|
|
·
|
By our company without cause (as defined in the agreement) or by Mr. Kempler with good reason (as defined in the agreement), he will be entitled to: (i) the sum of A$1 million provided we have sufficient capital requirements to fulfill this obligation within 90 days of termination date; (ii) business expenses that have not been reimbursed and accrued and unused vacation days; and (iii) the acceleration of the vesting of any unvested options to purchase ordinary shares which may be purchased during the remainder of the exercise period of such options.
|
|
·
|
By our company with cause (as defined in the agreement) or by Mr. Kempler without good reason (as defined in the agreement), he will be entitled to business expenses that have not been reimbursed and accrued and unused vacation days. Mr. Kempler will only be permitted to exercise unvested options to purchase shares that had been granted to him prior to the employment agreement.
|
|
·
|
Due to death or disability (as defined in the agreement), we shall pay Mr. Kempler or his estate, as applicable, all accrued base salary, pro-rata bonus, business expenses that have not been reimbursed and accrued, unused vacation days (and in the case of disability, less such amounts under any disability policy maintained by our company). Mr. Kempler or his estate, as applicable, will be entitled to exercise vested options for ordinary shares.
|
C.
|
Board Practices
|
|
·
|
incurred by the person in his or her capacity as an officer of our company or a subsidiary of our company provided that the liability does not arise out of a conduct involving a willful breach of duty in relation to our company or a subsidiary of our company; or
|
|
·
|
for costs and expenses incurred by that person defending proceedings, whatever their outcome.
|
D.
|
Employees
|
E.
|
Share Ownership
|
Name
|
Number of Ordinary Shares Beneficially Owned
(1)
|
Percentage of Ownership
(2)
|
||||||
Geoffrey P. Kempler
(3)
|
22,011,000 | 4.05 | % | |||||
Kathryn Andrews
|
- | * | ||||||
Dianne M. Angus
(4)
|
1,463,947 | * | ||||||
Peter A. Marks
(5)
|
1,043,111 | * | ||||||
Brian D. Meltzer
(6)
|
1,326,666 | * | ||||||
George W. Mihaly
(7)
|
1,226,666 | * | ||||||
Lawrence B. Gozlan
(8)
|
1,000,000 | * | ||||||
Ira Shoulson
|
- | * | ||||||
All directors and executive officers as a group (9 persons)
|
28,071,390 | 5.17 | % |
__________________
|
*
|
Less than 1%
|
|
(1)
|
Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission, and generally includes voting or investment power with respect to securities. Ordinary shares relating to options currently exercisable or exercisable within 60 days of the date of the above table are deemed outstanding for computing the percentage of the person holding such securities but are not deemed outstanding for computing the percentage of any other person. Except as indicated by footnote, and subject to community property laws where applicable, the persons named in the table above have sole voting and investment power with respect to all shares shown as beneficially owned by them.
|
|
(2)
|
The percentages shown are based on 543,209,289 consisting of 533,891,470 ordinary shares and 9,317,819 unlisted options, issued and outstanding as of August 24, 2015.
|
|
(3)
|
Includes options to purchase 4,000,000 ordinary shares that are exercisable for A$0.33 consideration on or before December 13, 2017. Of the 18,011,000 outstanding ordinary shares, 30,000 ordinary shares are held of record by Mr. Kempler, 14,165,000 ordinary shares are held by Baywick Pty Ltd., an Australian corporation owned by Mr. Kempler, 756,000 ordinary shares are held by Sadarajak Pty Ltd., an Australian corporation owned by Mr. Kempler, 90,000 ordinary shares are held of record by Crystal Triangle Pty Ltd., an Australian corporation owned by Mr. Kempler and 2,970,000 ordinary shares are held of record by NRB Developments Pty Ltd., an Australian corporation in which Mr. Kempler holds a 50% interest. Mr. Kempler may be deemed to be the beneficial owner of the ordinary shares held of record by Baywick Pty Ltd., Crystal Triangle Pty Ltd. and NRB Developments Pty Ltd.
|
|
(4)
|
Includes (i) options to purchase 160,000 ordinary shares that are exercisable for A$0.73 consideration on or before November 3, 2018; (ii) options to purchase 157,819 ordinary shares that are exercisable for A$0.25 consideration on or before March 20, 2017; (iii) options to purchase 1,000,000 ordinary shares that are exercisable for A$0.34 consideration on or before October 2, 2018; and (iv) 146,128 outstanding ordinary shares held of record by Ms. Dianne Angus.
|
|
(5)
|
Includes options to purchase 1,000,000 ordinary shares that are exercisable for A$0.33 consideration on or before December 13, 2017. The 43,111 outstanding ordinary shares are held of record by Lampam Pty Ltd, an Australian corporation owned by Mr. Peter Marks.
|
|
(6)
|
Includes options to purchase 1,000,000 ordinary shares that are exercisable for A$0.33 consideration on or before December 13, 2017. The 326,666 outstanding ordinary shares are held of record by Navigator Australia Ltd., a superannuation fund of Mr. Meltzer.
|
|
(7)
|
Includes options to purchase 1,000,000 ordinary shares that are exercisable for A$0.33 consideration on or before December 13, 2017. Of the 226,666 outstanding ordinary shares, 166,666 ordinary shares are held of record by Dr. Mihaly, 52,000 ordinary shares are held of record by Waide Pty Ltd., an Australian corporation owned by Dr. Mihaly, and 4,000 ordinary shares are held of record by each of Kieren Mihaly and Warwick Mihaly, Dr. Mihaly’s sons. Dr. Mihaly disclaims beneficial ownership of the ordinary shares held by his sons, Kieren Mihaly and Warwick Mihaly.
|
|
(8)
|
Includes options to purchase 1,000,000 ordinary shares that are exercisable for A$0.33 consideration on or before December 13, 2017.
|
As of June 30,
|
||||||||||||||||||||||||
2015
|
2014
|
2013
|
||||||||||||||||||||||
Amount
|
Weighted
average
exercise
price
|
Amount
|
Weighted
average
exercise
price
|
Amount
|
Weighted
average
exercise
price
|
|||||||||||||||||||
Options outstanding at the beginning of the year
|
16,375,582 | $ | 0.41 | 17,031,476 | $ | 0.23 | 10,147,683 | $ | 0.27 | |||||||||||||||
Granted
|
4,400,000 | $ | 0.28 | 3,926,490 | $ | 0.69 | 10,683,793 | $ | 0.34 | |||||||||||||||
Exercised
|
(180,000 | ) | -- | (4,582,384 | ) | $ | 0.11 | -- | -- | |||||||||||||||
Expired
|
(1,000,000 | ) | -- | -- | -- | (3,800,000 | ) | $ | 0.55 | |||||||||||||||
Lapsed
|
(200,000 | ) | -- | -- | -- | -- | -- | |||||||||||||||||
Options outstanding at the end of the year
|
19,395,582 | $ | 0.38 | 16,375,582 | $ | 0.41 | 17,031,476 | $ | 0.23 | |||||||||||||||
Options exercisable at the end of the year
|
19,395,582 | $ | 0.38 | 16,175,582 | $ | 0.40 | 16,010,786 | $ | 0.28 | |||||||||||||||
Options that may be granted as of the end of the year
|
15,319,202 | 19,629,202 | 21,135,692 |
ITEM 7.
|
MAJOR
SHAREHOLDERS AND
RELATED PARTY TRANSACTIONS
|
A.
|
Major Shareholders
|
B.
|
Related Party Transactions
|
A.
|
Interests of Experts and Counsel
|
ITEM 8.
|
FINANCIAL IN
FOR
MATION
|
A.
|
Financial Statements and Other Financial Information
|
B.
|
Significant Changes
|
ITEM 9.
|
THE OFFER
AND
LISTING
|
A.
|
Offer and Listing Details
|
Per Ordinary Share (A$)
|
||||||||
High
|
Low
|
|||||||
Fiscal Year Ended June 30,
|
||||||||
2011
|
0.38 | 0.11 | ||||||
2012
|
0.22 | 0.14 | ||||||
2013
|
0.31 | 0.14 | ||||||
2014
|
1.37 | 0.16 | ||||||
2015
|
0.36 | 0.14 | ||||||
Fiscal Year Ended June 30, 2013
:
|
||||||||
First Quarter
|
0.29 | 0.14 | ||||||
Second Quarter
|
0.31 | 0.20 | ||||||
Third Quarter
|
0.26 | 0.19 | ||||||
Fourth Quarter
|
0.25 | 0.20 | ||||||
Fiscal Year Ended June 30, 2014
:
|
||||||||
First Quarter
|
0.74 | 0.24 | ||||||
Second Quarter
|
0.85 | 0.38 | ||||||
Third Quarter
|
1.37 | 0.62 | ||||||
Fourth Quarter
|
0.30 | 0.16 | ||||||
Fiscal Year Ended June 30, 2015
:
|
||||||||
First Quarter
|
0.36 | 0.22 | ||||||
Second Quarter
|
0.25 | 0.17 | ||||||
Third Quarter
|
0.22 | 0.14 | ||||||
Fourth Quarter
|
0.26 | 0.14 | ||||||
Month Ended
:
|
||||||||
April 2015
|
0.15 | 0.14 | ||||||
May 2015
|
0.20 | 0.14 | ||||||
June 2015
|
0.26 | 0.15 | ||||||
July 2015
|
0.18 | 0.15 | ||||||
August 2015 (through
August 24
)
|
0.17 | 0.14 | ||||||
Per ADS (U.S. $)
|
||||||||
High
|
Low
|
|||||||
Fiscal Year Ended June 30,
|
||||||||
2010
|
3.35 | 1.02 | ||||||
2011
|
4.50 | 1.09 | ||||||
2012
|
2.31 | 1.40 | ||||||
2013
|
3.06 | 1.50 | ||||||
2014
|
13.29 | 1.47 | ||||||
Fiscal Year Ended June 30, 2013
:
|
||||||||
First Quarter
|
2.74 | 1.50 | ||||||
Second Quarter
|
3.06 | 1.81 | ||||||
Third Quarter
|
2.94 | 2.06 | ||||||
Fourth Quarter
|
2.45 | 2.12 | ||||||
Fiscal Year Ended June 30, 2014
:
|
||||||||
First Quarter
|
6.50 | 2.31 | ||||||
Second Quarter
|
7.87 | 3.62 | ||||||
Third Quarter
|
13.29 | 2.78 | ||||||
Fourth Quarter
|
2.71 | 1.47 | ||||||
Fiscal Year Ended June 30, 2015
:
|
||||||||
First Quarter
|
2.94 | 1.93 | ||||||
Second Quarter
|
2.29 | 1.40 | ||||||
Third Quarter
|
1.71 | 1.07 | ||||||
Fourth Quarter
|
1.85 | 1.08 | ||||||
Month Ended
:
|
||||||||
April 2015
|
1.30 | 1.08 | ||||||
May 2015
|
1.85 | 1.15 | ||||||
June 2015
|
1.62 | 1.14 | ||||||
July 2015
|
1.28 | 1.12 | ||||||
August 2015 (through
August 24)
|
1.19 | 0.86 |
B.
|
Plan of Distribution
|
C.
|
Markets
|
D.
|
Selling Shareholders
|
E.
|
Dilution
|
F.
|
Expenses of the Issue
|
ITEM 10.
|
ADDITIO
NA
L INFORMATION
|
A.
|
Share Capital
|
B.
|
Memorandum and Articles of Association
|
C.
|
Material Contracts
|
D.
|
Exchange Controls
|
E.
|
Taxation
|
|
·
|
Retain access to the full CGT discount for discount capital gains of foreign resident individuals in respect of the increase in the value of a CGT asset that occurred before 9 May 2013; and
|
|
·
|
Remove the CGT discount for discount capital gains for foreign resident individuals that arise after 8 May 2013.
|
|
●
|
Core activities, which are experimental activities whose outcome cannot be known or determined in advance, but can only be determined by applying a systematic progression of work;
|
|
●
|
Core activities conducted for the purpose of generating new knowledge (including new knowledge in the form of new or improved processes and materials); or
|
|
●
|
Supporting activities that are directly related and designed to support (a) and (b).
|
|
●
|
a 45% refundable tax offset for eligible companies with an aggregated turnover of less than $20 million per annum; or
|
|
●
|
a non-refundable 40% tax offset for all other eligible companies.
|
|
·
|
you will be required to allocate “excess distributions” or gain recognized upon the disposition of ADRs ratably over your holding period for the ADSs. An “excess distribution” is the amount by which distributions during a taxable year in respect of an ADS exceed 125% of the average annual distributions during the three preceding taxable years (or, if shorter, your holding period for the ADSs).
|
|
·
|
the amount allocated to each year during which we are considered a PFIC, other than the year of the distribution or disposition, will be subject to tax at the highest individual or corporate tax rate, as the case may be, in effect for that year and an interest charge will be imposed with respect to the resulting tax liability allocated to each such year,
|
|
·
|
the amount allocated to the current taxable year and any taxable year before we became a PFIC will be taxable as ordinary income in the current year, and
|
|
·
|
you will be required to file an annual return on Internal Revenue Service Form 8621.
|
|
·
|
a direct or indirect owner of a pass-through entity, including a trust or estate, that is a direct or indirect shareholder of a PFIC,
|
|
·
|
a shareholder of a PFIC that is a shareholder of another PFIC, or
|
|
·
|
a 50%-or-more shareholder of a foreign corporation that is not a PFIC and that directly or indirectly owns stock of a PFIC.
|
F.
|
Dividends and Paying Agents
|
G.
|
Statement by Experts
|
H.
|
Documents on Display
|
I.
|
Subsidiary Information
|
ITEM 11.
|
QUANTITA
TIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
ITEM 12.
|
DESCRI
PT
ION OF SECURITIES OTHER THAN EQUITY SECURITIES
|
Persons Depositing or Withdrawing Shares Must Pay:
|
For:
|
|
• US$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)
|
|
• Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property
• Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates
|
• US$0.005 (or less) per ADS
|
• Any cash distribution to you
|
|
• A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs
|
• Distribution of securities distributed to holders of deposited securities which are distributed by the depositary to ADS holders
|
|
• US$1.50 (or less) per ADS
|
• Transfers, combination and split-up of ADSs
|
|
• Expenses of the depositary
|
• Cable, telex and facsimile transmissions (when expressly provided in the deposit agreement)
• Converting foreign currency to U.S. dollars
|
|
• Taxes and other governmental charges the depositary or the custodian have to pay on any ADS or share underlying an ADS, for example, stock transfer taxes, stamp duty or withholding taxes
|
• As necessary
|
|
• Any charges incurred by the depositary or its agents for servicing the deposited securities
|
• As necessary
|
ITEM 13.
|
DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES
|
ITEM 14.
|
MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS
|
ITEM 15.
|
CONTROLS AND PROCEDURES
|
|
·
|
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;
|
|
·
|
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
|
|
·
|
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use of disposition of the company’s assets that could have a material effect on the financial statements.
|
ITEM 16.
|
RESERV
E
D
|
Year Ended June 30,
|
||||||||
Services Rendered
|
2015
|
2014
|
||||||
Audit (1)
|
$ | A160,158 | $ | A145,187 | ||||
Audit-Related (2)
|
$ | A256,113 | $ | A187,422 | ||||
Other (3)
|
$ | A83,640 | $ | A65,000 | ||||
Total
|
$ | A499,911 | $ | A397,609 |
ITEM 16E.
|
PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS
|
ITEM 16F.
|
CHANGES IN REGISTRANT’S CERTIFYING ACCOUNTANT
|
ITEM 17.
|
FINANCIAL STATEMENTS
|
ITEM 18.
|
FINANCIAL STATEMENTS
|
Page
|
|
Index to Consolidated Financial Statements
|
F-0
|
Report of Independent Registered Public Accounting Firm
|
F-1
|
Consolidated
Statements of Financial Position
|
F-3
|
Consolidated
Statements of Profit or Loss and Other Comprehensive Income
|
F-4
|
Consolidated Cash Flow Statements
|
F-5
|
Consolidated Statements of Changes in Shareholders’ Equity
|
F-6
|
Notes to Consolidated Financial Statements
|
F-7
|
ITEM 19.
|
EXHI
BI
TS
|
Exhibit
Number
|
Exhibit Description
|
|
Incorporated by
Reference
|
Form
|
Exhibit
|
|
Filing Date/
Period End
Date
|
|||||
1
|
Constitution of Registrant.
|
20-F
|
1.1
|
|
6/30/09
|
|||
2.1
|
Deposit Agreement dated March 23, 2001, as amended and restated as of December 21, 2007, among the Registrant, the Bank of New York, as Depositary, and owners and holders from time to time of ADRs issued thereunder, including the Form of American Depositary Receipts.
|
F-6 POS
|
1
|
|
12/21/07
|
|||
4.1
|
License Agreement dated January 1, 2001, between the Registrant and The General Hospital Corporation.
|
20-F
|
|
5/29/02
|
||||
4.2
|
Variation Agreement dated August 8, 2001, between the Registrant and The General Hospital Corporation, which amends the License Agreement dated January 1, 2001, between the parties.
|
20-F
|
|
|
5/29/02
|
|||
4.3
|
Agreement to Provide Accounting, Administration, Corporate Advice and Company Secretarial Services dated February 23, 2000, between the Registrant and Malvern Administrative Services (now The CFO solution).
|
20-F
|
|
5/29/02
|
||||
4.4
|
Second Amendment to Exclusive License Agreement dated January 1, 2001, between the Registrant and The General Hospital Corporation dated March 15, 2004.
|
20-F
|
4.6
|
|
6/30/04
|
|||
4.5
|
Settlement Agreement dated July 28, 2004, among the Registrant, P.N. Gerolymatos S.A, or PNG, Mr. Gerolymatos, GHC, Professor Ashley Bush, Dr. Rudolph Tanzi and Dr. Robert Cherny and the ancillary agreements of even date therewith exhibited thereto, including the Patent Assignment and Settlement Agreement among the Registrant and PNG, Patent Rights Security Agreement among the Registrant and PNG and the Derivatives Agreement among the Registrant and PNG.
|
20-F
|
4.21
|
|
6/30/04
|
|||
4.6
|
Prana Biotechnology Limited, 2004 American Depository Share (ADS) Option Plan.
|
6-K
|
Annexure A
to Item 1
|
|
11/3/04
|
|||
4.7
|
Prana Biotechnology Limited, 2004 Employees’, Directors’ and Consultants’ Share and Option Plan.
|
6-K
|
Annexure B
to Item 1
|
11/3/04
|
||||
4.8
|
Fourth Research Funding and Intellectual Property Assignment Agreement dated December 1, 2009.
|
20-F
|
4.9
|
6/30/12
|
||||
4.9
|
Fifth Research Funding and Intellectual Property Assignment Agreement dated December 1, 2012.
|
20-F
|
4.9
|
6/30/13
|
4.10*
|
Sixth Research Funding and Intellectual Property Assignment Agreement dated November 7, 2014.
|
|||||||
4.11
|
Employment Agreement dated September 21, 2007, among the Registrant and Mr. Kempler.
|
20-F
|
4.19
|
6/30/07
|
||||
4.12
|
Letter Agreements effective as of June 12, 2007 between the Registrant and Ms. Dianne Angus.
|
20-F
|
4.21
|
6/30/07
|
||||
4.13
|
Placement Confirmation Letter dated September 8, 2009, between the Registrant and BAM Capital LLC.
|
20-F
|
4.25
|
|
6/30/07
|
|||
4.14
|
Manufacturing Services Agreement for PBT2 HCI Supply dated August 19, 2013 between the Registrant and Dr. Reddy’s Laboratories Limited.
|
20-F
|
4.30
|
6/30/13
|
||||
4.15
|
Amendments to Manufacturing Services Agreement for PBT2 HCI Supply dated August 19, 2013 between the Registrant and Dr. Reddy’s Laboratories Limited, as amended: Amendment No. 1 effective September 26, 2013; and Amendment No. 2 effective August 31, 2013.
|
20-F
|
4.35
|
6/30/14
|
||||
4.16
|
Manufacturing Services Agreement for PBT434 API supply dated March 28, 2014
|
20-F
|
4.36
|
6/30/14
|
||||
4.17*
|
Master Service Agreement between the Registrant and Certara Portugal dated January 22, 2015
|
|||||||
4.18*
|
Master Service Agreement between the Registrant and d3 Medicine LLC dated March 17, 2015
|
|||||||
8.1*
|
List of Subsidiaries of the Registrant.
|
|
||||||
12.1*
|
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act, as amended.
|
|||||||
12.2*
|
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act, as amended.
|
|
||||||
13.1*
|
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
||||||
13.2*
|
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
||||||
15.1*
|
Consent of PricewaterhouseCoopers.
|
|
Page Number
|
|
F-1
|
|
F-3
|
|
F-4
|
|
F-5
|
|
F-6
|
|
F-7
|
/s/PricewaterhouseCoopers
|
Melbourne, Australia
|
August 26, 2015
|
|
PRANA BIOTECHNOLOGY LIMITED
|
June 30,
|
|||||||||||
Notes
|
2015
|
2014
|
|||||||||
Assets
|
|||||||||||
Current Assets
|
|||||||||||
Cash and cash equivalents
|
34,909,574 | 34,167,018 | |||||||||
Trade and other receivables
|
5 | 6,521,154 | 7,285,409 | ||||||||
Other current assets
|
6 | 313,465 | 96,883 | ||||||||
Total Current Assets
|
41,744,193 | 41,549,310 | |||||||||
Non-Current Assets
|
|||||||||||
Property and equipment, net of accumulated depreciation of A$322,342 and $345,238, respectively
|
7 | 44,727 | 47,557 | ||||||||
Other non-current assets
|
6 | 45,462 | 43,988 | ||||||||
Total Non-Current Assets
|
90,189 | 91,545 | |||||||||
Total Assets
|
41,834,382 | 41,640,855 | |||||||||
Liabilities
|
|||||||||||
Current Liabilities
|
|||||||||||
Trade and other payables
|
8 | 2,152,015 | 3,358,358 | ||||||||
Other financial liabilities
|
9 | 12,076 | 98,398 | ||||||||
Provisions
|
10 | 554,615 | 494,784 | ||||||||
Total Current Liabilities
|
2,718,706 | 3,951,540 | |||||||||
Non-Current Liabilities
|
|||||||||||
Provisions
|
10 | 2,412 | 3,028 | ||||||||
Total Non-Current Liabilities
|
2,412 | 3,028 | |||||||||
Total Liabilities
|
2,721,118 | 3,954,568 | |||||||||
Net Assets
|
39,113,264 | 37,686,287 | |||||||||
Equity
|
|||||||||||
Issued capital
2015: 533,891,470 fully paid ordinary shares
Nil options over fully paid ordinary shares
2014: 488,646,960 fully paid ordinary shares
Nil options over fully paid ordinary shares
|
13 | 146,895,714 | 140,009,415 | ||||||||
Reserves
|
14 | 9,363,181 | 8,937,434 | ||||||||
Accumulated deficit during the development stage
|
15 | (117,145,631 | ) | (111,260,562 | ) | ||||||
Total Equity
|
39,113,264 | 37,686,287 |
PRANA BIOTECHNOLOGY LIMITED
|
Years ended June 30,
|
|||||||||||||||
Notes
|
2015
|
2014
|
2013
|
||||||||||||
Revenues from ordinary activities
|
2 | 176,842 | 363,775 | 150,867 | |||||||||||
Other income
|
2 | 6,317,438 | 7,845,396 | 4,488,526 | |||||||||||
Research and development expenses
|
3 | (12,298,167 | ) | (14,908,098 | ) | (8,203,822 | ) | ||||||||
Corporate personnel expenses
|
3 | (2,344,337 | ) | (2,059,642 | ) | (2,298,426 | ) | ||||||||
Intellectual property expenses
|
3 | (257,299 | ) | (477,079 | ) | (294,894 | ) | ||||||||
Auditor and accounting expenses
|
3 | (416,271 | ) | (342,609 | ) | (166,086 | ) | ||||||||
Travel expenses
|
3 | (125,532 | ) | (421,013 | ) | (131,710 | ) | ||||||||
Public relations and marketing expenses
|
3 | (87,851 | ) | (358,597 | ) | (136,186 | ) | ||||||||
Depreciation expenses
|
3 | (31,587 | ) | (22,384 | ) | (23,130 | ) | ||||||||
Other expenses
|
3 | (1,626,076 | ) | (2,142,179 | ) | (1,169,407 | ) | ||||||||
Interest expense - ADDF
|
- | (29,978 | ) | (17,676 | ) | ||||||||||
Foreign exchange gain (loss)
|
3 | 4,721,449 | (746,593 | ) | 140,761 | ||||||||||
Gain (loss) on fair valuation of financial liabilities
|
3 | 86,322 | (30,238 | ) | (126,059 | ) | |||||||||
Loss before income tax expense
|
(5,885,069 | ) | (13,329,239 | ) | (7,787,242 | ) | |||||||||
Income tax expense
|
4 | - | - | - | |||||||||||
Loss for the year
|
(5,885,069 | ) | (13,329,239 | ) | (7,787,242 | ) | |||||||||
Other comprehensive loss
|
- | - | - | ||||||||||||
Total comprehensive loss for the year
|
16a | (5,885,069 | ) | (13,329,239 | ) | (7,787,242 | ) | ||||||||
Loss per share (basic and diluted - cents per share)
|
20 | (1.17 | ) | (3.11 | ) | (2.30 | ) | ||||||||
Weighted average number of ordinary shares used in computing basic and diluted net loss per share
|
502,714,982 | 428,047,123 | 338,700,006 |
Years Ended June 30,
|
|||||||||||||||
Notes
|
2015
|
2014
|
2013
|
||||||||||||
Cash Flows from Operating Activities
|
|||||||||||||||
Payments to suppliers and employees
|
(18,124,103 | ) | (18,011,310 | ) | (10,650,823 | ) | |||||||||
Interest received
|
216,317 | 377,587 | 93,789 | ||||||||||||
Grants received
|
228,541 | 2,500 | 107,097 | ||||||||||||
R&D tax refund
|
6,808,171 | 4,095,000 | 2,492,683 | ||||||||||||
Other
|
- | - | 6,000 | ||||||||||||
Net cash flows used in operating activities
|
16(a) | (10,871,074 | ) | (13,536,223 | ) | (7,951,254 | ) | ||||||||
Cash Flows from Investing Activities
|
|||||||||||||||
Payment for payroll and rental security deposits
|
(154,077 | ) | - | (6,151 | ) | ||||||||||
Payments for purchase of plant and equipment
|
(28,757 | ) | (23,048 | ) | (22,000 | ) | |||||||||
Net cash flows used in investing activities
|
(182,834 | ) | (23,048 | ) | (28,151 | ) | |||||||||
Cash Flows from Financing Activities
|
|||||||||||||||
Proceeds from exercise of options and issue of securities
|
7,128,142 | 37,110,325 | 16,260,806 | ||||||||||||
Payment of share issue costs
|
(284,931 | ) | (1,339,369 | ) | (1,015,775 | ) | |||||||||
Proceeds from borrowings
|
- | - | 337,000 | ||||||||||||
Repayment of borrowings
|
- | (810,164 | ) | - | |||||||||||
Net cash flows provided by financing activities
|
6,843,211 | 34,960,792 | 15,582,031 | ||||||||||||
Net increase (decrease) in cash and cash equivalents
|
(4,210,697 | ) | 21,401,521 | 7,602,626 | |||||||||||
Opening cash and cash equivalents brought forward
|
34,167,018 | 13,346,760 | 5,636,469 | ||||||||||||
Exchange rate adjustments on cash and cash equivalents held in foreign currencies
|
4,953,253 | (581,263 | ) | 107,665 | |||||||||||
Closing cash and cash equivalents carried forward
|
16(b) | 34,909,574 | 34,167,018 | 13,346,760 |
Notes
|
Number of Shares
|
Issued Capital
|
Reserves
|
Accumulated
Deficit During Development Stage
|
Total Equity
|
||||||||||||||||
Balance, June 30, 2012
|
297,980,818 | 86,134,077 | 9,633,451 | (90,144,081 | ) | 5,623,447 | |||||||||||||||
Transactions with owners in their capacity as owners:
|
|||||||||||||||||||||
Issuance of shares in connection with private placement, net of costs
|
13(b)
|
58,141,030 | 10,629,011 | - | - | 10,629,011 | |||||||||||||||
Issuance of shares in connection with share purchase plan, net of costs
|
13(b)
|
10,370,488 | 1,570,863 | - | - | 1,570,863 | |||||||||||||||
Issuance of shares in connection with At-The-Market facility, net of costs
|
13(b)
|
15,008,090 | 3,023,160 | - | - | 3,023,160 | |||||||||||||||
Non-cash issuance of shares to consultants
|
13(b)
|
110,000 | 22,000 | - | - | 22,000 | |||||||||||||||
Non-cash issuance of options to employees
|
14(b)
|
- | - | 86,969 | - | 86,969 | |||||||||||||||
Non-cash issuance of options to consultants
|
14(b)
|
- | - | 215,083 | - | 215,083 | |||||||||||||||
Non-cash issuance of options to directors
|
14(b)
|
- | - | 591,422 | - | 591,422 | |||||||||||||||
83,629,608 | 15,245,034 | 893,474 | - | 16,138,508 | |||||||||||||||||
Net loss
|
15
|
- | - | - | (7,787,242 | ) | (7,787,242 | ) | |||||||||||||
Total comprehensive loss for the year
|
- | - | - | (7,787,242 | ) | (7,787,242 | ) | ||||||||||||||
Balance, June 30, 2013
|
381,610,426 | 101,379,111 | 10,526,925 | (97,931,323 | ) | 13,974,713 | |||||||||||||||
Transactions with owners in their capacity as owners:
|
|||||||||||||||||||||
Issuance of shares in connection with At-The-Market facility, net of costs
|
13(b)
|
85,108,500 | 30,818,030 | - | - | 30,818,030 | |||||||||||||||
Issuance of shares in connection with share purchase plan, net of costs
|
13(c)
|
1,000,000 | 276,950 | - | - | 276,950 | |||||||||||||||
Non-cash issuance of options to employees
|
14(b)
|
- | - | 33,824 | - | 33,824 | |||||||||||||||
Non-cash issuance of options to consultants
|
14(b)
|
- | - | 959,084 | - | 959,084 | |||||||||||||||
Issuance of shares in connection with exercise of options, net of costs
|
13(b) & 14(b)
|
20,928,034 | 7,535,324 | (2,582,399 | ) | - | 4,952,925 | ||||||||||||||
107,036,534 | 38,630,304 | (1,589,491 | ) | - | 37,040,813 | ||||||||||||||||
Net loss
|
- | - | - | (13,329,239 | ) | (13,329,239 | ) | ||||||||||||||
Total comprehensive loss for the year
|
- | - | - | (13,329,239 | ) | (13,329,239 | ) | ||||||||||||||
Balance, June 30, 2014
|
488,646,960 | 140,009,415 | 8,937,434 | (111,260,562 | ) | 37,686,287 | |||||||||||||||
Transactions with owners in their capacity as owners:
|
|||||||||||||||||||||
Issuance of shares in connection with At-The-Market facility, net of costs
|
13(b)
|
44,954,510 | 7,129,242 | (284,931) | - | - | 7,129,242 | ||||||||||||||
Issuance of shares in connection with share purchase plan, net of costs
|
13(c)
|
110,000 | 16,500 | - | - | 16,500 | |||||||||||||||
Non-cash issuance of options to employees
|
14(b)
|
- | - | 170,397 | - | 170,397 | |||||||||||||||
Non-cash issuance of options to consultants
|
14(b)
|
- | - | 280,838 | - | 280,838 | |||||||||||||||
Issuance of shares in connection with exercise of options, net of costs
|
13(b) & 14(b)
|
180,000 | 25,488 | (25,488 | ) | - | - | ||||||||||||||
45,244,510 | 6,886,299 | 425,747 | - | 7,312,046 | |||||||||||||||||
Net loss
|
- | - | - | (5,885,069 | ) | (5,885,069 | ) | ||||||||||||||
Total comprehensive loss for the year
|
- | - | - | (5,885,069 | ) | (5,885,069 | ) | ||||||||||||||
Balance, June 30, 2015
|
533,891,470 | 146,895,714 | 9,363,181 | (117,145,631 | ) | 39,113,264 |
|
·
|
The Company continues to pursue raising additional funds through alternative funding structures and has a strong history of raising capital. The Group had an "at the market” (ATM) facility through which it could raise additional funds of up to US$50.0 million by the sale of American Depositary Receipts ("ADRs"). This facility, which was established through the filing of a shelf registration statement on Form F-3 with the United States Securities and Exchange Commission in November, 2014 has been a successful source of raising funds. As at the date of this report the Company sold 4.5 million of its ADRs for aggregate gross proceeds of approximately A$7.1 million (US$5.5 million). In prior reporting periods, the Company has raised A$39.4 million (US$37.0 million) under a previous ATM facility.
|
|
·
|
The Company has on issue a total of 20.01 million unlisted, unexercised options. The options have exercise prices ranging from A$0.25 to A$1.12. If all unlisted options were exercised, the Company would receive consideration of A$7.5 million in total. Although the exercise of options may be available, it is not in the Company’s control to receive this consideration.
|
|
·
|
Notwithstanding, in the event that the Company will not have sufficient funds to effect its current plans through the above mentioned methods, the Company has the ability to scale down its operations and prioritize its research and development programs.
|
Class of Fixed Asset | Depreciation Rate |
Furniture and fittings | 5-33% |
Computer equipment | 33% |
Plant and equipment | 10-33% |
Leasehold improvements | 33% |
|
• the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and
|
·
|
assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet, and
|
·
|
income and expenses for each income statement are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions), and
|
·
|
all resulting exchange differences are recognized as a separate component of equity.
|
(j)
|
Employee Benefits
|
(k)
|
Provisions
|
(l)
|
Cash and Cash Equivalents
|
(m)
|
Revenue from ordinary activities
|
(n)
|
Grants
|
(o)
|
Goods and Services Tax (“GST”)
|
(p)
|
Trade and Other Payables
|
(q)
|
Borrowings
|
(r)
|
Share-Based Payments
|
(s)
|
Loss Per Share
|
(t)
|
Share Capital
|
(u)
|
Trade and Other Receivables
|
(v)
|
Comparative Figures
|
(w)
|
Parent Information
|
(x)
|
New Accounting Standards And Interpretations
|
Pronouncement
|
Title (Issue date)
|
Effective date
|
Amendment to IFRS 11
|
Joint arrangements on acquisition of an interest in a joint operation
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
Amendment to IAS 16 and IAS 41
|
Property, plant and equipment and Agriculture, regarding bearer plants
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
Amendment to IAS 16 and IAS 38
|
Property, plant and equipment and Intangible assets on depreciation and amortization
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
IFRS 14
|
Regulatory deferral accounts
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
Amendments to IAS 27
|
Separate financial statements on the equity method
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
Amendments to IFRS 10 and IAS 28
|
Consolidated financial statements and Investments in associates and joint ventures
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
Annual improvements 2014 to IFRS 5
|
Non-current assets held for sale and discontinued operations regarding methods of disposal
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
Annual improvements 2014 to IFRS 7
|
Financial instruments: Disclosures, (with consequential amendments to IFRS 1) regarding servicing contracts
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
Annual improvements 2014 to IAS 19
|
Employee benefits regarding discount rates
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
Annual improvements 2014 to IAS 34
|
Interim financial reporting regarding disclosure of information
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
Amendment to IAS 1
|
Presentation of financial statements on the disclosure initiative
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
Amendment to IFRS 10 and IAS 28
|
Investment entities applying the consolidation exception
|
Annual periods beginning on or after January 1, 2016
Earlier application is permitted.
|
IFRS 15
|
Revenue from contracts with customers
|
Annual periods beginning on or after January 1, 2017
Earlier application is permitted.
|
IFRS 9
|
Financial instruments
|
Annual periods beginning on or after January 1, 2018
Earlier application is permitted.
|
Years Ended June 30,
|
||||||||||||
2015
|
2014
|
2013
|
||||||||||
2.
REVENUE AND OTHER INCOME
FROM CONTINUING OPERATIONS
|
||||||||||||
Other revenue
|
||||||||||||
Interest
|
176,842 | 363,775 | 150,867 | |||||||||
Total other revenue
|
176,842 | 363,775 | 150,867 | |||||||||
Other income
|
||||||||||||
R&D Tax Incentive
|
6,088,897 | 7,802,947 | 4,408,761 | |||||||||
Michael J Fox Foundation Grant
|
- | 39,949 | 73,765 | |||||||||
Other Grants
|
228,541 | 2,500 | 6,000 | |||||||||
Total other income
|
6,317,438 | 7,845,396 | 4,488,526 | |||||||||
Total revenue and other income from continuing operations
|
6,494,280 | 8,209,171 | 4,639,393 |
Years Ended June 30,
|
|||||||||||||
Notes
|
2015
|
2014
|
2013
|
||||||||||
3.
EXPENSES FROM ORDINARY ACTIVITIES
|
|||||||||||||
Research and development expenses
|
3(a) and 3(b)
|
12,298,167 | 14,908,098 | 8,203,822 | |||||||||
Corporate personnel expenses
|
|||||||||||||
Employee expenses
|
3(b)
|
885,893 | 751,004 | 649,430 | |||||||||
Equity based payments to employees
|
3(b)
|
170,397 | 33,824 | 18,252 | |||||||||
Consultant and director expenses
|
930,393 | 773,601 | 761,584 | ||||||||||
Equity-based payments to consultants and directors
|
297,338 | 438,639 | 800,833 | ||||||||||
Defined contribution superannuation expenses
|
3(b)
|
60,316 | 62,574 | 68,327 | |||||||||
Total corporate personnel expense*
|
2,344,337 | 2,059,642 | 2,298,426 | ||||||||||
Intellectual property expenses
|
|||||||||||||
Overseas
|
206,748 | 195,092 | 145,233 | ||||||||||
Local
|
50,551 | 281,987 | 149,661 | ||||||||||
Total intellectual property expense
|
257,299 | 477,079 | 294,894 | ||||||||||
Depreciation of non-current assets
|
|||||||||||||
Laboratory equipment
|
853 | 44 | 2,831 | ||||||||||
Computer equipment
|
27,797 | 19,605 | 17,569 | ||||||||||
Furniture and fittings
|
2,937 | 2,735 | 2,730 | ||||||||||
Total depreciation expense
|
31,587 | 22,384 | 23,130 | ||||||||||
Other expenses
|
|||||||||||||
Corporate compliance
|
421,958 | 487,632 | 251,552 | ||||||||||
Administrative and office expenses
|
865,241 | 1,365,151 | 634,552 | ||||||||||
Computer expenses
|
30,023 | 22,316 | 21,609 | ||||||||||
Insurance
|
147,679 | 103,497 | 84,679 | ||||||||||
Office rental under operating lease
|
161,175 | 163,583 | 177,015 | ||||||||||
Interest Expense - ADDF
|
- | 29,978 | 17,676 | ||||||||||
Total other expenses
|
1,626,076 | 2,172,157 | 1,187,083 | ||||||||||
Auditor and accounting expenses
|
416,271 | 342,609 | 166,086 | ||||||||||
Travel expenses
|
125,532 | 421,013 | 131,710 | ||||||||||
Public relations and marketing expenses
|
87,851 | 358,597 | 136,186 | ||||||||||
Foreign exchange (gain) loss
|
(4,721,449 | ) | 746,593 | (140,761 | ) | ||||||||
(Gain) loss on fair valuation of financial liabilities
|
(86,322 | ) | 30,238 | 126,059 | |||||||||
Total expenses
|
12,379,349 | 21,538,410 | 12,426,635 | ||||||||||
*Corporate personnel expenses excludes salaries and fees paid to employees and consultants involved in research and development activities.
|
|||||||||||||
Years Ended June 30,
|
|||||||||||||
(a) Research and development expenses (1) and (2)
|
2015 | 2014 | 2013 | ||||||||||
Personnel expenses related to research and development
|
1,866,915 | 1,827,934 | 777,272 | ||||||||||
Research and development expenses
|
10,431,252 | 13,080,164 | 7,426,550 | ||||||||||
Total research and development expenses
|
12,298,167 | 14,908,098 | 8,203,822 | ||||||||||
|
(1) Research and development expenses consist of expenses paid for contracted research and development activities conducted by third parties on behalf of the Company.
|
Years Ended June 30,
|
||||||||||||
(b) Employee benefits expenses
|
2015
|
2014
|
2013
|
|||||||||
Employee expenses
|
2,668,199 | 1,948,607 | 1,413,368 | |||||||||
Equity payments to employees
|
170,397 | 33,824 | 382,678 | |||||||||
Defined contribution superannuation expenses
|
185,408 | 121,165 | 90,217 | |||||||||
Total employee benefits expenses
|
3,024,004 | 2,103,596 | 1,886,263 |
Years Ended June 30,
|
||||||||||||
2015
|
2014
|
2013
|
||||||||||
4.
INCOME TAX
|
||||||||||||
(a)
The
prima facie
tax on
net (loss) before tax is reconciled to the income tax is as follows:
|
||||||||||||
Prima facie tax on net (loss) before income tax at 30% (2015, 2014 & 2013: 30%)
|
(1,765,521 | ) | (3,998,772 | ) | (2,336,173 | ) | ||||||
Effect of lower tax rates of tax on overseas income
|
(41 | ) | (43 | ) | (499 | ) | ||||||
Add tax effect of:
|
||||||||||||
(Over)/Under provision of income tax in previous year relating to a correction of estimates (1)
|
3,071,631 | 2,214,342 | 1,408,791 | |||||||||
Equity issued for nil consideration
|
140,651 | 1,269,857 | 274,642 | |||||||||
Research and development tax incentive refund
|
(2,153,737 | ) | (7,180,486 | ) | (1,039,919 | ) | ||||||
Gain/(loss) on fair value of financial liabilities
|
25,897 | (30,238 | ) | (9,381 | ) | |||||||
Other
|
1,549 | 5,761 | 1,766 | |||||||||
Deferred tax asset not recognized
|
679,571 | 7,719,579 | 1,700,772 | |||||||||
Income tax expense attributable to loss before income tax
|
- | - | - | |||||||||
(b)
Potential deferred tax asset at June 30, 2015, 2014 and 2013 in respect of: tax losses not brought to account is (2):
|
38,463,614 | 39,143,186 | 35,566,969 | |||||||||
Temporary differences
|
3,934,146 | (37,806 | ) | (338,714 | ) | |||||||
Years Ended June 30,
|
||||||||
2015
|
2014
|
|||||||
5.
TRADE AND OTHER RECEIVABLES
|
||||||||
Grant receivable
|
55,699 | - | ||||||
Accrued interest income
|
4,255 | 43,730 | ||||||
R&D tax incentive receivable
|
6,461,212 | 7,180,486 | ||||||
Goods and services tax receivable
|
(12 | ) | 61,193 | |||||
Total Trade and Other Receivables
|
6,521,154 | 7,285,409 |
Years Ended June 30,
|
||||||||
2015
|
2014
|
|||||||
6.
OTHER ASSETS
|
||||||||
Current
|
||||||||
Prepayments
|
159,963 | 62,771 | ||||||
Payroll term deposit
|
152,603 | - | ||||||
Other receivables
|
899 | 34,112 | ||||||
Total
|
313,465 | 96,883 | ||||||
Non-current
|
||||||||
Rental term deposit
|
45,462 | 43,988 | ||||||
Total
|
45,462 | 43,988 |
Years Ended June 30,
|
|||||||||||
Notes
|
2015
|
2014
|
|||||||||
7.
PROPERTY AND EQUIPMENT
|
|||||||||||
Gross carrying amount
|
|||||||||||
Balance at beginning of year
|
392,795 | 369,747 | |||||||||
Additions
|
28,757 | 23,048 | |||||||||
Disposals
|
(54,483 | ) | - | ||||||||
Balance at end of year
|
367,069 | 392,795 | |||||||||
Accumulated depreciation
|
|||||||||||
Balance at beginning of year
|
(345,238 | ) | (322,854 | ) | |||||||
Disposals
|
54,483 | - | |||||||||
Depreciation expense
|
3 | (31,587 | ) | (22,384 | ) | ||||||
Balance at end of year
|
(322,342 | ) | (345,238 | ) | |||||||
Net book value at end of year
|
44,727 | 47,557 |
Years Ended June 30,
|
||||||||
2015
|
2014
|
|||||||
Laboratory equipment, at cost
|
112,631 | 116,007 | ||||||
Less accumulated depreciation
|
(110,963 | ) | (113,486 | ) | ||||
Total laboratory equipment
|
1,668 | 2,521 | ||||||
Computer equipment, at cost
|
140,382 | 185,641 | ||||||
Less accumulated depreciation
|
(103,771 | ) | (149,190 | ) | ||||
Total computer equipment
|
36,611 | 36,451 | ||||||
Furniture and fittings, at cost
|
38,398 | 37,598 | ||||||
Less accumulated depreciation
|
(31,949 | ) | (29,012 | ) | ||||
Total furniture and fittings
|
6,449 | 8,586 | ||||||
Leasehold improvements, at cost
|
75,659 | 75,659 | ||||||
Less accumulated depreciation
|
(75,659 | ) | (75,659 | ) | ||||
Total leasehold improvements
|
- | - | ||||||
Total
|
44,727 | 47,557 |
Years Ended June 30,
|
||||||||
2015
|
2014
|
|||||||
8.
TRADE AND OTHER PAYABLES
|
||||||||
Trade creditors
|
362,493 | 651,152 | ||||||
Accrued research and development expenses
|
1,299,492 | 2,222,881 | ||||||
Accrued intellectual property expenses
|
- | 60,380 | ||||||
Accrued corporate personnel expenses
|
535 | 361 | ||||||
Accrued audit and accounting fees
|
415,911 | 336,866 | ||||||
Accrued travel expenses
|
- | 10,609 | ||||||
Accrued marketing expenses
|
- | 22,645 | ||||||
Other accrued expenses
|
73,584 | 53,464 | ||||||
Total
|
2,152,015 | 3,358,358 |
Years Ended June 30,
|
||||||||||||||||
2015
|
2014
|
2015
|
2014
|
|||||||||||||
9.
FINANCIAL LIABILITIES
|
No.
|
No.
|
A$ | A$ | ||||||||||||
Current
|
||||||||||||||||
Warrants over ordinary shares (a)
|
612,397 | 612,397 | 12,076 | 98,398 | ||||||||||||
Total
|
12,076 | 98,398 |
(1) Movements in provisions
|
Movements in each class of provision during the financial year are set out below:
|
Years Ended June 30,
|
||||||||
2015
|
2014
|
|||||||
Annual leave
|
||||||||
Carrying amount at start of year
|
217,646 | 179,609 | ||||||
Charged/(credited) to profit or loss
|
||||||||
-additional provisions recognized
|
199,667 | 152,041 | ||||||
-unused amounts reversed
|
- | - | ||||||
Amounts used during the year
|
(155,490 | ) | (114,004 | ) | ||||
Carrying amount at end of year
|
261,823 | 217,646 | ||||||
Long service leave
|
||||||||
Carrying amount at start of year
|
280,166 | 239,700 | ||||||
Charged/(credited) to profit or loss
|
||||||||
-additional provisions recognized
|
15,038 | 40,466 | ||||||
-unused amounts reversed
|
- | - | ||||||
Amounts used during the year
|
- | - | ||||||
Carrying amount at end of year
|
295,204 | 280,166 | ||||||
TOTAL
|
557,027 | 497,812 |
Years Ended June 30,
|
||||||||
2015
|
2014
|
|||||||
Long service leave obligation expected to be settled after 12 months
|
292,792 | 277,138 |
11.
|
COMMITMENTS AND CONTINGENCIES
|
Years Ended June 30,
|
|||||||||||||
Notes
|
2015
|
2014
|
2013
|
||||||||||
13. ISSUED CAPITAL
|
|||||||||||||
(a) Issued Capital
|
|||||||||||||
533,891,470 (2014: 488,646,960) fully paid ordinary shares
|
13(b)
|
144,194,070 | 137,307,771 | 98,677,467 | |||||||||
Nil (2014: Nil) options for fully paid ordinary shares
|
13(c)
|
2,701,644 | 2,701,644 | 2,701,644 | |||||||||
146,895,714 | 140,009,415 | 101,379,111 |
(b) Movements in Issued Shares
|
June 30,
|
||||||||||||||||||||||||
2015
|
2014
|
2013
|
||||||||||||||||||||||
No.
|
No.
|
A$
|
No.
|
No.
|
A$
|
|||||||||||||||||||
Beginning of the year
|
488,646,960 | 137,307,771 | 381,610,426 | 98,677,467 | 297,980,818 | 83,432,433 | ||||||||||||||||||
Movement during the year
|
45,244,510 | 6,886,299 | 107,036,534 | 38,630,304 | 83,629,608 | 15,245,034 | ||||||||||||||||||
End of the year
|
533,891,470 | 144,194,070 | 488,646,960 | 137,307,771 | 381,610,426 | 98,677,467 |
Date
|
Details
|
Notes
|
Number
|
Issue Price
|
A$ | |||||||||||
Year ended June 30, 2012
|
22,694,035 | 3,793,258 | ||||||||||||||
August 24, 2012
|
Shares to investors as part of at-the-market facility
|
1,364,190 | 0.18 | 239,238 | ||||||||||||
August 27, 2012
|
Shares to investors as part of at-the-market facility
|
1,656,440 | 0.17 | 288,162 | ||||||||||||
August 28, 2012
|
Shares to investors as part of at-the-market facility
|
52,000 | 0.17 | 8,970 | ||||||||||||
August 29, 2012
|
Shares to investors as part of at-the-market facility
|
164,770 | 0.17 | 28,252 | ||||||||||||
August 31, 2012
|
Shares to investors as part of at-the-market facility
|
347,000 | 0.17 | 58,771 | ||||||||||||
September 3, 2012
|
Shares to investors as part of at-the-market facility
|
816,330 | 0.17 | 138,954 | ||||||||||||
September 4, 2012
|
Shares to investors as part of at-the-market facility
|
169,060 | 0.17 | 27,909 | ||||||||||||
September 14, 2012
|
Shares to investors as part of at-the-market facility
|
1,249,450 | 0.19 | 242,432 | ||||||||||||
September 17, 2012
|
Shares to investors as part of at-the-market facility
|
2,507,610 | 0.20 | 507,067 | ||||||||||||
September 18, 2012
|
Shares to investors as part of at-the-market facility
|
354,500 | 0.20 | 70,973 | ||||||||||||
September 25, 2012
|
Shares to investors as part of at-the-market facility
|
1,196,500 | 0.25 | 296,530 | ||||||||||||
September 26, 2012
|
Shares to investors as part of at-the-market facility
|
189,210 | 0.24 | 46,289 | ||||||||||||
September 27, 2012
|
Shares to investors as part of at-the-market facility
|
121,350 | 0.22 | 27,055 | ||||||||||||
September 28, 2012
|
Shares to investors as part of at-the-market facility
|
20,700 | 0.23 | 4,665 | ||||||||||||
October 8, 2012
|
Shares to investors as part of private placement
|
32,500,000 | 0.18 | 6,012,500 | ||||||||||||
March 1, 2013
|
Non cash share issue in consideration for services provided by consultants
|
(i)
|
110,000 | 0.20 | 22,000 | |||||||||||
March 7, 2013
|
Shares to investors as part of at-the-market facility
|
1,843,240 | 0.27 | 502,879 | ||||||||||||
March 7, 2013
|
Shares to investors as part of at-the-market facility
|
1,499,870 | 0.27 | 407,541 |
Date
|
Details
|
Notes
|
Number
|
Issue Price
|
A$ |
April 8, 2013
|
Shares to investors as part of private placement
|
25,641,030 | 0.20 | 5,000,000 | ||||||||||||
April 8, 2013
|
Shares to investors as part of at-the-market facility
|
1,045,150 | 0.21 | 218,981 | ||||||||||||
April 8, 2013
|
Shares to investors as part of at-the-market facility
|
244,740 | 0.22 | 53,110 | ||||||||||||
April 8, 2013
|
Shares to investors as part of at-the-market facility
|
165,980 | 0.22 | 36,284 | ||||||||||||
May 3, 2013
|
Share Purchase Plan
|
10,370,488 | 0.19 | 2,022,245 | ||||||||||||
Security issuance costs
|
(1,015,775 | ) | ||||||||||||||
Year ended June 30, 2013
|
83,629,608 | 15,245,034 | ||||||||||||||
August 2, 2013
|
Shares to investors as part of at-the-market facility
|
1,469,780 | 0.40 | 588,216 | ||||||||||||
August 5, 2013
|
Shares to investors as part of at-the-market facility
|
465,980 | 0.38 | 176,592 | ||||||||||||
August 6, 2013
|
Shares to investors as part of at-the-market facility
|
3,601,550 | 0.39 | 1,413,617 | ||||||||||||
August 7, 2013
|
Shares to investors as part of at-the-market facility
|
2,517,590 | 0.38 | 956,832 | ||||||||||||
August 30, 2013
|
Exercise of options – consultants
|
150,000 | 0.35 | 52,140 | ||||||||||||
August 30, 2013
|
Exercise of options – consultants
|
100,000 | 0.12 | 11,700 | ||||||||||||
August 30, 2013
|
Exercise of options – consultants
|
86,625 | 0.14 | 12,266 | ||||||||||||
August 30, 2013
|
Exercise of options – consultants
|
100,000 | 0.12 | 11,700 | ||||||||||||
August 30, 2013
|
Exercise of options – investors
|
10,000,000 | 0.39 | 3,857,143 | ||||||||||||
August 30, 2013
|
Shares to investors as part of at-the-market facility
|
1,167,610 | 0.57 | 662,809 | ||||||||||||
September 9, 2013
|
Shares to investors as part of at-the-market facility
|
2,160,950 | 0.58 | 1,261,265 | ||||||||||||
September 10, 2013
|
Shares to investors as part of at-the-market facility
|
1,395,610 | 0.56 | 786,494 | ||||||||||||
September 11, 2013
|
Shares to investors as part of at-the-market facility
|
523,120 | 0.55 | 288,606 | ||||||||||||
September 12, 2013
|
Shares to investors as part of at-the-market facility
|
2,056,760 | 0.52 | 1,071,557 | ||||||||||||
October 3, 2013
|
Exercise of options – employees
|
97,418 | 0.18 | 17,577 | ||||||||||||
October 3, 2013
|
Exercise of options – employees
|
625,000 | 0.45 | 282,828 | ||||||||||||
October 25, 2013
|
Exercise of options – consultants
|
60,000 | 0.14 | 8,496 | ||||||||||||
October 25, 2013
|
Exercise of options – employees
|
217,478 | 0.14 | 30,795 | ||||||||||||
November 4, 2013
|
Shares to investors as part of at-the-market facility
|
6,745,750 | 0.48 | 3,209,209 | ||||||||||||
November 5, 2013
|
Shares to investors as part of at-the-market facility
|
143,700 | 0.48 | 69,054 | ||||||||||||
November 4, 2013
|
Exercise of options – employees
|
722,419 | 0.42 | 300,405 | ||||||||||||
November 6, 2013
|
Shares to investors as part of at-the-market facility
|
8,380 | 0.49 | 4,070 | ||||||||||||
November 25, 2013
|
Exercise of options – consultants
|
200,000 | 0.40 | 80,786 | ||||||||||||
December 13, 2013
|
Exercise of options – employees
|
73,200 | 0.35 | 25,444 | ||||||||||||
December 20, 2013
|
Exercise of options – employees
|
81,750 | 0.14 | 11,576 | ||||||||||||
December 20, 2013
|
Exercise of options – consultants
|
100,000 | 0.40 | 40,393 | ||||||||||||
January 3, 2014
|
Exercise of options – investors
|
1,700,000 | 0.35 | 593,622 | ||||||||||||
January 28, 2014
|
Exercise of options – investors
|
500,000 | 0.35 | 174,595 | ||||||||||||
February 6, 2014
|
Exercise of options – investors
|
3,928,900 | 0.35 | 1,371,931 | ||||||||||||
February 6, 2014
|
Exercise of options – employees
|
50,000 | 0.35 | 17,380 | ||||||||||||
February 21, 2014
|
Exercise of options – employees
|
60,000 | 0.28 | 16,800.00 | ||||||||||||
February 21, 2014
|
Exercise of options – employees
|
146,128 | 0.25 | 36,532 | ||||||||||||
February 21, 2014
|
Exercise of options – employees
|
157,818 | 0.35 | 54,858 | ||||||||||||
February 26, 2014
|
Exercise of options – employees
|
34,220 | 0.51 | 17,298 | ||||||||||||
February 26, 2014
|
Exercise of options – employees
|
47,700 | 0.35 | 16,581 | ||||||||||||
March 11, 2014
|
Exercise of options – consultants
|
200,000 | 0.40 | 80,786 | ||||||||||||
March 11, 2014
|
Exercise of options – employees
|
60,000 | 0.35 | 20,856 | ||||||||||||
March 11, 2014
|
Exercise of options – employees
|
66,500 | 0.28 | 18,620 | ||||||||||||
March 11, 2014
|
Exercise of options – consultants
|
1,000,000 | 0.26 | 260,000 | ||||||||||||
March 11, 2014
|
Exercise of options – employees
|
146,128 | 0.25 | 36,532 | ||||||||||||
March 11, 2014
|
Shares to investors as part of at-the-market facility
|
980,130 | 1.23 | 1,202,928 |
Date
|
Details
|
Notes
|
Number
|
Issue Price
|
A$ |
March 12, 2014
|
Shares to investors as part of at-the-market facility
|
41,760 | 1.18 | 49,339 | ||||||||||||
March 14, 2014
|
Shares to investors as part of at-the-market facility
|
1,594,220 | 1.11 | 1,767,019 | ||||||||||||
March 17, 2014
|
Shares to investors as part of at-the-market facility
|
2,280,750 | 1.05 | 2,405,397 | ||||||||||||
April 3, 2014
|
Exercise of options – investors
|
216,750 | 0.35 | 75,687 | ||||||||||||
April 3, 2014
|
Shares to investors as part of at-the-market facility
|
22,339,170 | 0.31 | 6,963,613 | ||||||||||||
April 4, 2014
|
Shares to investors as part of at-the-market facility
|
17,290,080 | 0.27 | 4,607,964 | ||||||||||||
April 7, 2014
|
Shares to investors as part of at-the-market facility
|
18,325,610 | 0.25 | 4,672,819 | ||||||||||||
April 7, 2014
|
Non cash share issue in consideration for services provided by consultants
|
(i)
|
1,000,000 | 0.25 | 252,750 | |||||||||||
June 30, 2014
|
Non cash share issue in consideration for services provided by consultants
|
- | - | 24,200 | ||||||||||||
Security issuance costs
|
- | - | (1,339,369 | ) | ||||||||||||
Year ended June 30, 2014
|
107,036,534 | 38,630,304 | ||||||||||||||
July 1, 2014
|
Reverse proposed issue to a consultant
|
- | - | (24,200 | ) | |||||||||||
July 21, 2014
|
Non cash share issue in consideration for services provided by consultants
|
(i)
|
110,000 | 0.23 | 25,300 | |||||||||||
July 21, 2014
|
Exercise of options – employees
|
180,000 | - | 25,488 | ||||||||||||
February 23, 2015
|
Shares to investors as part of at-the-market facility
|
35,631,690 | 0.15 | 5,304,319 | ||||||||||||
February 24, 2015
|
Shares to investors as part of at-the-market facility
|
2,538,820 | 0.14 | 357,270 | ||||||||||||
June 2, 2015
|
Shares to investors as part of at-the-market facility
|
6,784,000 | 0.22 | 1,466,553 | ||||||||||||
June 30, 2015
|
Non cash share issue in consideration for services provided by consultants
|
- | - | 16,500 | ||||||||||||
Security issuance costs
|
- | - | (284,931 | ) | ||||||||||||
Year ended June 30, 2015
|
45,244,510 | 6,886,299 |
(c) Movements in Options
|
June 30,
|
||||||||||||||||||||||||
2015
|
2014
|
2013
|
||||||||||||||||||||||
Number of Options
|
A$
|
Number of Options
|
A$
|
Number of Options
|
A$
|
|||||||||||||||||||
Beginning of the year
|
- | 2,701,644 | - | 2,701,644 | - | 2,701,644 | ||||||||||||||||||
End of the year*
|
- | 2,701,644 | - | 2,701,644 | - | 2,701,644 |
(d) Terms and Conditions of Issued Capital
|
Ordinary shares
|
Ordinary shares have the right to receive dividends as declared and, in the event of a winding up of the Company, to participate in the proceeds from the sale of all surplus assets in proportion to the number of and amounts paid up on shares held. Ordinary shares entitle their holder to vote, either in person or by proxy, at a meeting of the Company’s shareholders.
|
Options
|
Option holders do not have the right to receive dividends and are not entitled to vote at a meeting of the Company’s shareholders. Options may be exercised at any time from the date they vest to the date of their expiration. Share options convert into ordinary shares on a one for one basis on the date they are exercised.
|
(e) Shares Issued after Reporting Date
|
Years Ended June 30,
|
|||||||||||||
Notes
|
2015
|
2014
|
2013
|
||||||||||
(a)
Share Based Payments
|
|||||||||||||
19,395,582 (2014: 18,542,577) options for fully paid ordinary shares
|
14(b)
|
7,394,184 | 6,968,437 | 8,557,928 | |||||||||
Nil (2014: Nil) options for ADRs
|
14(c)
|
1,515,434 | 1,515,434 | 1,515,434 | |||||||||
612,397 (2014: 612,397) warrants for ADRs
|
14(d)
|
453,563 | 453,563 | 453,563 | |||||||||
9,363,181 | 8,937,434 | 10,526,925 |
Years Ended June 30,
|
||||||||||||||||||||||||
2015
|
2014
|
2013
|
||||||||||||||||||||||
Number of Options
|
Comp.
Expense (A$)
|
Number of Options
|
Comp.
Expense (A$)
|
Number of Options
|
Comp.
Expense (A$)
|
|||||||||||||||||||
Beginning of the year
|
18,542,577 | 6,968,437 | 35,544,121 | 8,557,928 | 28,360,328 | 7,664,454 | ||||||||||||||||||
Issued during the year
|
4,400,000 | 451,235 | 3,926,490 | 992,908 | 10,683,793 | 893,474 | ||||||||||||||||||
Expired during the year
|
(3,166,995 | ) | - | - | - | (3,500,000 | ) | - | ||||||||||||||||
Forfeited during the year
|
(200,000 | ) | - | - | - | - | - | |||||||||||||||||
Exercised during the year
|
(180,000 | ) | (25,488 | ) | (20,928,034 | ) | (2,582,399 | ) | - | - | ||||||||||||||
End of the year
|
19,395,582 | 7,394,184 | 18,542,577 | 6,968,437 | 35,544,121 | 8,557,928 |
14. RESERVES (continued)
|
Year ended June 30, 2013:
|
Year ended June 30, 2014:
|
Year ended June 30, 2015:
|
14. RESERVES (continued)
|
Years Ended June 30,
|
||||||||||||||||||||||||
2015
|
2014
|
2013
|
||||||||||||||||||||||
Number of Options
|
Comp.
Expense (A$)
|
Number of Options
|
Comp.
Expense (A$)
|
Number of Options
|
Comp.
Expense (A$)
|
|||||||||||||||||||
Beginning of the year
|
- | 1,515,434 | - | 1,515,434 | 380,000 | 1,515,434 | ||||||||||||||||||
Expiration of options (1)
|
- | - | - | - | (380,000 | ) | - | |||||||||||||||||
End of the year
|
- | 1,515,434 | - | 1,515,434 | - | 1,515,434 |
Years Ended June 30,
|
||||||||||||||||||||||||
2015
|
2014
|
2013
|
||||||||||||||||||||||
Number of Warrants
|
Comp.
Expense (A$)
|
Number of Warrants
|
Comp.
Expense (A$)
|
Number of Warrants
|
Comp.
Expense (A$)
|
|||||||||||||||||||
Beginning of the year
(1)
|
- | 453,563 | - | 453,563 | - | 453,563 | ||||||||||||||||||
Beginning of the year (2)
|
612,397 | - | 612,397 | - | 612,397 | - | ||||||||||||||||||
End of the year
|
612,397 | 453,563 | 612,397 | 453,563 | 612,397 | 453,563 |
(e) Terms and Conditions of Reserves
|
Options and warrants
|
Option holders and warrant holders do not have the right to receive dividends and are not entitled to vote at a meeting of the Company’s shareholders. Options and warrants may be exercised at any time from the date they vest to the date of their expiration. Share options are exercisable into ordinary shares on a one for one basis on the date they are exercised. Options granted under the 2004 ADS Plan are exercisable into ADRs, being one option for one ADR, which equals ten ordinary shares, on the date they are exercised.
|
(f) Options and Warrants Issued after Reporting Date
|
Years Ended June 30,
|
||||||||
2015
|
2014
|
|||||||
15.
ACCUMULATED DEFICIT DURING DEVELOPMENT STAGE
|
||||||||
Balance at beginning of year
|
(111,260,562 | ) | (97,931,323 | ) | ||||
Net loss for the year
|
(5,885,069 | ) | (13,329,239 | ) | ||||
Balance at end of year
|
(117,145,631 | ) | (111,260,562 | ) |
Years Ended June 30,
|
||||||||||||
2015
|
2014
|
2013
|
||||||||||
16.
CASH FLOW INFORMATION
|
||||||||||||
(a) Reconciliation of Net Loss to Net Cash Flows From Operations
|
||||||||||||
Net loss
|
(5,885,069 | ) | (13,329,239 | ) | (7,787,242 | ) | ||||||
Non-cash items
|
||||||||||||
Depreciation of property and equipment
|
31,587 | 22,384 | 23,130 | |||||||||
Non-cash issue of equity in consideration of operating expenses
|
468,835 | 1,269,857 | 893,477 | |||||||||
Loss on disposal of plant and equipment
|
- | - | (150 | ) | ||||||||
Foreign exchange (gain) loss
|
(4,952,735 | ) | 581,263 | (110,816 | ) | |||||||
(Gain) loss on fair value of financial liabilities
|
(86,322 | ) | 37,473 | 197,898 | ||||||||
Changes in assets and liabilities
|
||||||||||||
Decrease (increase) in trade and other receivables
|
764,255 | (3,761,471 | ) | (1,973,102 | ) | |||||||
Decrease (increase) in other current assets
|
(63,979 | ) | 15,359 | (43,567 | ) | |||||||
(Decrease) increase in trade and other payables
|
(1,206,343 | ) | 1,582,980 | 817,041 | ||||||||
(Decrease) in other current liabilities
|
- | (33,332 | ) | (17,499 | ) | |||||||
Increase in provision for employee entitlements
|
59,215 | 78,503 | 49,576 | |||||||||
Net cash flows used in operating activities
|
(10,871,074 | ) | (13,536,223 | ) | (7,951,254 | ) | ||||||
(b) Reconciliation of Cash and Cash Equivalents
|
||||||||||||
Cash and cash equivalents balance comprises:
|
||||||||||||
- cash and cash equivalents on hand
|
34,909,574 | 34,167,018 | 13,346,760 | |||||||||
Closing cash and cash equivalents balance
|
34,909,574 | 34,167,018 | 13,346,760 |
17. EXPENDITURE COMMITMENTS
|
18. SHARE BASED PAYMENTS
|
(a) Employee and Consultant Plans
|
Years Ended June 30,
|
||||||||||||||||||||||||
2015
|
2014
|
2013
|
||||||||||||||||||||||
Number of Options
|
Weighted Average Exercise Price (A$)
|
Number of Options
|
Weighted Average Exercise Price (A$)
|
Number of Options
|
Weighted Average Exercise Price (A$)
|
|||||||||||||||||||
Beginning of the year
|
16,375,582 | 0.41 | 17,031,476 | 0.23 | 6,347,683 | 0.14 | ||||||||||||||||||
Issued during the year
|
4,400,000 | 0.28 | 3,926,490 | 0.69 | 10,683,793 | 0.34 | ||||||||||||||||||
Exercised during the year
|
(180,000 | ) | - | (4,582,384 | ) | 0.11 | - | - | ||||||||||||||||
Expired during the year
|
(1,000,000 | ) | 0.25 | - | - | - | - | |||||||||||||||||
Lapsed during the year
|
(200,000 | ) | 1.12 | - | - | - | - | |||||||||||||||||
Forfeited during the year
|
- | - | - | - | - | - | ||||||||||||||||||
Outstanding at year end
|
19,395,582 | 0.38 | 16,375,582 | 0.41 | 17,031,476 | 0.23 | ||||||||||||||||||
Exercisable at year end
|
19,395,582 | 0.38 | 16,175,582 | 0.40 | 16,010,786 | 0.28 |
Series
|
Grant Date
|
Expiry Date
|
Exercise Price
$A
|
Share options
2015
|
Share options
2014
|
|||||||||||
PBTAA
|
October 25, 2013
|
October 24, 2018
|
0.61 | 200,000 | 200,000 | |||||||||||
PBTAB
|
June 8, 2010
|
August 7, 2014
|
0.00 | - | 180,000 | |||||||||||
PBTAB
|
October 3, 2014
|
October 2, 2018
|
0.34 | 1,000,000 | - | |||||||||||
PBTAC
|
June 26, 2013
|
June 25, 2018
|
0.37 | 1,649,573 | 1,649,573 | |||||||||||
PBTAD
|
November 4, 2013
|
November 3, 2018
|
0.73 | 360,000 | 360,000 | |||||||||||
PBTAE
|
December 13, 2013
|
December 11, 2018
|
1.04 | 1,200,000 | 1,200,000 | |||||||||||
PBTAF
|
February 7, 2014
|
February 5, 2019
|
1.12 | 100,000 | 300,000 | |||||||||||
PBTAG
|
April 7, 2014
|
April 6, 2018
|
0.25 | 1,200,000 | 1,200,000 | |||||||||||
PBTAH
|
February 19, 2015
|
February 18, 2020
|
0.26 | 2,000,000 | - | |||||||||||
PBTAQ
|
December 12, 2012
|
December 13, 2017
|
0.33 | 8,500,000 | 8,500,000 | |||||||||||
PBTAR
|
May 27, 2015
|
May 25, 2020
|
0.27 | 1,400,000 | - | |||||||||||
PBTAU
|
December 19, 2011
|
December 19, 2014
|
0.25 | - | 1,000,000 | |||||||||||
PBTAW
|
March 21, 2012
|
March 20, 2017
|
0.25 | 1,119,519 | 1,119,519 | |||||||||||
PBTAY
|
August 5, 2013
|
August 4, 2018
|
0.66 | 306,490 | 306,490 | |||||||||||
PBTAZ
|
October 2, 2013
|
October 1, 2018
|
0.66 | 360,000 | 360,000 | |||||||||||
Total
|
19,395,582 | 16,375,582 | ||||||||||||||
Weighted average remaining contractual life of options outstanding at end of period
|
3.04 years
|
3.42 years
|
·
|
risk-free interest rate of 2.24% for 2015, 3.26% for 2014 and 2.83% for 2013;
|
·
|
no dividends;
|
·
|
expected volatility of 85.74% for 2015, 134.50% for 2014 and 57.15% for 2013;
|
·
|
expected life of 4.77 for 2015, 4.69 years for 2014 and 5.00 years for 2013;
|
·
|
underlying share price of $0.18 for 2015, $0.50 for 2014 and $0.21 for 2013; and
|
·
|
exercise price of $0.28 for 2015, $0.69 for 2014 and $0.34 for 2013.
|
Series
|
Grant Date
|
Exercise Price per Share
A$
|
Share Price at Grant Date
A$
|
Expected Share Price Volatility
|
Years to Expiry
|
Dividend Yield
|
Risk-free Interest Rate
|
|||||||||||||||||||
PBTAQ
|
December 12, 2012
|
0.33 | 0.21 | 52.30 | % | 5.00 | 0 | % | 2.73 | % | ||||||||||||||||
PBTAC
|
June 26, 2013
|
0.37 | 0.23 | 83.10 | % | 5.00 | 0 | % | 3.23 | % | ||||||||||||||||
PBTAY
|
August 5, 2013
|
0.66 | 0.38 | 62.00 | % | 5.00 | 0 | % | 3.05 | % | ||||||||||||||||
PBTAZ
|
October 2, 2013
|
0.66 | 0.41 | 61.00 | % | 5.00 | 0 | % | 3.24 | % | ||||||||||||||||
PBTAA
|
October 25, 2013
|
0.61 | 0.38 | 63.60 | % | 5.00 | 0 | % | 3.31 | % | ||||||||||||||||
PBTAD
|
November 4, 2013
|
0.73 | 0.44 | 68.80 | % | 5.00 | 0 | % | 3.46 | % | ||||||||||||||||
PBTAE
|
December 13, 2013
|
1.04 | 0.69 | 70.70 | % | 5.00 | 0 | % | 3.45 | % | ||||||||||||||||
PBTAF
|
February 7, 2014
|
1.12 | 1.18 | 58.50 | % | 5.00 | 0 | % | 3.44 | % | ||||||||||||||||
PBTAG
|
April 7, 2014
|
0.25 | 0.23 | 289.40 | % | 4.00 | 0 | % | 3.02 | % | ||||||||||||||||
PBTAB
|
October 3, 2014
|
0.34 | 0.22 | 130.50 | % | 4.00 | 0 | % | 2.71 | % | ||||||||||||||||
PBTAH
|
February 19, 2015
|
0.26 | 0.16 | 74.80 | % | 5.00 | 0 | % | 2.00 | % | ||||||||||||||||
PBTAR
|
May 27, 2015
|
0.27 | 0.17 | 69.40 | % | 5.00 | 0 | % | 2.25 | % |
Years Ended June 30,
|
||||||||||||
2015
|
2014
|
2013
|
||||||||||
Number of Shares
|
Number of Shares
|
Number of Shares
|
||||||||||
Beginning of the year
|
12,987,715 | 7,405,331 | 7,295,331 | |||||||||
Issued during the year (1)
|
290,000 | 5,582,384 | 110,000 | |||||||||
End of the financial year
|
13,277,715 | 12,987,715 | 7,405,331 |
Years Ended June 30,
|
||||||||||||||||||||||||
2015
|
2014
|
2013
|
||||||||||||||||||||||
Number of Options
|
Weighted Average Exercise Price
|
Number of Options
|
Weighted Average Exercise Price
|
Number of Options
|
Weighted Average Exercise Price
|
|||||||||||||||||||
Beginning of the year
|
- | - | - | - | 380,000 | A$ |
US$5.00
(5.48
|
) | ||||||||||||||||
Expired during the year
1
|
- | - | - | - | (380,000 | ) | A$ |
US$5.00
(5.48
|
) | |||||||||||||||
Outstanding at year end
|
- | - | - | - | - | - | ||||||||||||||||||
Exercisable at year end
1
|
- | - | - | - | - | - |
Years Ended June 30,
|
||||||||||||
2015
|
2014
|
2013
|
||||||||||
20.
LOSS PER SHARE
|
||||||||||||
Basic and diluted loss per share (cents per share)
|
(1.17 | ) | (3.11 | ) | (2.30 | ) | ||||||
Weighted average number of ordinary shares on issue used in the calculation of basic and diluted loss per share
|
502,714,982 | 428,047,123 | 338,700,006 |
21.
KEY MANAGEMENT PERSONNEL COMPENSATION
|
2015
|
2014
|
|||||||
Short-term employee benefits
|
1,554,843 | 1,139,860 | ||||||
Post-employment benefits
|
96,324 | 77,775 | ||||||
Long-term benefits
|
2,733 | 17,615 | ||||||
Termination benefits
|
- | - | ||||||
Share-based payments
|
170,397 | 33,824 | ||||||
1,824,297 | 1,269,074 |
Years Ended June 30,
|
||||||||||||
2015
|
2014
|
2013
|
||||||||||
22.
AUDITORS’ REMUNERATION
|
||||||||||||
- audit and review fees: current year financial reports
|
160,158 | 145,187 | 164,060 | |||||||||
- audit and review fees: internal controls for Sarbanes Oxley requirement
|
256,113 | 187,422 | - | |||||||||
- audit and review fees: other assurance services
|
83,640 | 65,000 | - | |||||||||
499,911 | 397,609 | 164,060 |
23.
|
RELATED PARTY TRANSACTIONS
|
a.
|
Equity Interests in Subsidiaries
|
b.
|
Key Management Personnel Remuneration
|
The Directors of Prana during the year:
|
Short Term Benefits
|
Post-Employment
|
Long Term Benefits
|
Equity
|
|||||||||||||||||||||
2015
Directors’ remuneration
|
Base Fee
A$
|
Bonus
A$
|
Superannuation
Contribution
A$
|
Long-service Leave
A$
|
Options
A$
|
Total
A$
|
||||||||||||||||||
Geoffrey Kempler (1)
|
421,689 | 100,000 | 35,000 | (224 | ) | - | 556,465 | |||||||||||||||||
Brian Meltzer
|
50,000 | - | 35,000 | - | - | 85,000 | ||||||||||||||||||
George Mihaly
|
75,000 | - | - | - | - | 75,000 | ||||||||||||||||||
Peter Marks
|
60,000 | - | - | - | - | 60,000 | ||||||||||||||||||
Lawrence Gozlan
|
50,000 | - | - | - | - | 50,000 | ||||||||||||||||||
Ira Shoulson (2)
|
250,648 | - | - | - | - | 250,648 | ||||||||||||||||||
1,007,337 | - | 70,000 | (224 | ) | - | 1,077,113 |
|
(1)Base Fee includes movements in annual leave provision for Mr. Kempler accrued in accordance with his employment contract. During the 2015 fiscal year, Mr. Kempler received a A$100,000 incentive bonus which he was awarded in 2012.
|
|
(2)Includes consulting fees paid to Prof. Ira Shoulson in the amount of A$205,426.
|
Short Term Benefits
|
Post-Employment
|
Long Term Benefits
|
Equity
|
|||||||||||||||||||||
2014
Directors’ remuneration
|
Base Fee
A$
|
Bonus
A$
|
Superannuation
Contribution
A$
|
Long-service Leave
A$
|
Options
A$
|
Total
A$
|
||||||||||||||||||
Geoffrey Kempler (1)
|
444,389 | - | 25,000 | 8,601 | - | 477,990 | ||||||||||||||||||
Brian Meltzer
|
50,000 | - | 35,000 | - | - | 85,000 | ||||||||||||||||||
George Mihaly
|
75,000 | - | - | - | - | 75,000 | ||||||||||||||||||
Peter Marks
|
60,000 | - | - | - | - | 60,000 | ||||||||||||||||||
Lawrence Gozlan
|
50,000 | - | - | - | - | 50,000 | ||||||||||||||||||
Ira Shoulson (2)
|
5,625 | - | - | - | - | 5,625 | ||||||||||||||||||
685,014 | - | 60,000 | 8,601 | - | 753,615 |
|
(1)Base Fee includes movements in annual leave provision for Mr. Kempler accrued in accordance with his employment contract.
|
|
(2)Prof. Ira Shoulson was appointed to the Board on May 13, 2014;
|
Short Term Benefits
|
Post-Employment
|
Long Term Benefits
|
Equity
|
|||||||||||||||||||||
2013
Directors’ remuneration
|
Base Fee
A$
|
Bonus
A$
|
Superannuation
Contribution
A$
|
Long-service Leave
A$
|
Options
A$
|
Total
A$
|
||||||||||||||||||
Geoffrey Kempler (1) (2)
|
428,278 | - | 25,000 | 11,980 | 295,711 | 760,969 | ||||||||||||||||||
Brian Meltzer (2)
|
62,500 | - | 25,000 | - | 73,928 | 161,428 | ||||||||||||||||||
George Mihaly (2)
|
75,000 | - | - | - | 73,928 | 148,928 | ||||||||||||||||||
Peter Marks (2)
|
57,500 | - | - | - | 73,928 | 131,428 | ||||||||||||||||||
Lawrence Gozlan (2)
|
45,000 | - | - | - | 73,928 | 118,928 | ||||||||||||||||||
668,278 | - | 50,000 | 11,980 | 591,423 | 1,321,681 |
|
(1)Base Fee includes movements in annual leave provision for Mr. Kempler accrued in accordance with his employment contract.
|
|
(2)The Directors received unlisted options during the year ended June 30, 2013. The option prices were calculated using the Black-Scholes Model applying the following inputs:
|
Grant Date: December 12, 2012
|
Volatility: 52.30%
|
Exercise Price: A$0.33
|
Risk-free Interest Rate: 2.73%
|
Stock Price: A$0.21
|
Dividend Yield: 0%
|
Years to Expiry: 5.00
|
Option Price: A$0.0739
|
23. RELATED PARTY TRANSACTIONS (continued)
|
Short Term Benefits
|
Post-Employment
|
Long Term Benefits
|
Equity
|
|||||||||||||||||||||
2015
Executives’ Remuneration
|
Base Fee
A$
|
Other
A$
|
Superannuation
Contribution
A$
|
Long-service Leave
A$
|
Options
A$
|
Total
A$
|
||||||||||||||||||
Phillip Hains (3)
|
100,000 | - | - | - | - | 100,000 | ||||||||||||||||||
Dianne Angus (1) (2)
|
326,346 | - | 18,783 | 2,874 | 170,397 | 518,401 | ||||||||||||||||||
Kathryn Andrews (4)
|
81,233 | - | 7,541 | 82 | - | 88,857 | ||||||||||||||||||
Richard Revelins (5)
|
39,926 | - | - | - | - | 39,926 | ||||||||||||||||||
547,506 | - | 26,324 | 2,957 | 170,397 | 747,184 | |||||||||||||||||||
|
(1) Base Fee includes movements in annual leave provision for Ms Dianne Angus and Ms Kathryn Andrews accrued in accordance with their employment contracts.
|
|
(2) Ms. Angus received unlisted options during the year ended June 30, 2014. The option prices were calculated using the Black-Scholes Model applying the following inputs:
|
Grant Date: October 3, 2014
|
Volatility: 130.5%
|
Exercise Price: A$0.34
|
Risk-free Interest Rate: 2.71%
|
Stock Price: A$0.22
|
Dividend Yield: 0%
|
Years to Expiry: 4.00
|
Option Price: A$0.1704
|
|
(3) Mr. Hains retired from his appointment as Acting Chief Financial Officer on November 4, 2014;
|
|
(4) Ms. Andrews was appointed as Chief Financial Officer on November 4, 2014;
|
|
(5) Mr. Richard Revelins retired from his appointment as Company Secretary and Chief Financial Officer on November 4, 2014.
|
Short Term Benefits
|
Post-Employment
|
Long Term Benefits
|
Equity
|
|||||||||||||||||||||
2014
Executives’ Remuneration
|
Base Fee
A$
|
Other
A$
|
Superannuation
Contribution
A$
|
Long-service Leave
A$
|
Options
A$
|
Total
A$
|
||||||||||||||||||
Richard Revelins
|
80,013 | - | - | - | - | 80,013 | ||||||||||||||||||
Dianne Angus (1) (2)
|
324,833 | - | 17,775 | 9,015 | 33,824 | 385,447 | ||||||||||||||||||
Phillip Hains (3)
|
50,000 | - | - | - | - | 50,000 | ||||||||||||||||||
454,846 | - | 17,775 | 9,015 | 33,824 | 515,460 |
|
(1) Base Fee includes movements in annual leave provision for Ms
.
Dianne Angus accrued in accordance with his employment contract.
|
|
(2) Ms. Angus received unlisted options during the year ended June 30, 2014. The option prices were calculated using the Black-Scholes Model applying the following inputs:
|
Grant Date: November 4, 2013
|
Volatility: 68.80%
|
Exercise Price: A$0.73
|
Risk-free Interest Rate: 3.46%
|
Stock Price: A$0.44
|
Price: A$0.44
Dividend Yield: 0%
|
Years to Expiry: 5.00
|
Option Price: A$0.2114
|
|
(3) Mr. Hains was appointed as Acting Chief Financial Officer on May 1, 2014.
|
Short Term Benefits
|
Post-Employment
|
Long Term Benefits
|
Equity
|
|||||||||||||||||||||
2013
Executives’ Remuneration
|
Base Fee
A$
|
Other
A$
|
Superannuation
Contribution
A$
|
Long-service Leave
A$
|
Options
A$
|
Total
A$
|
||||||||||||||||||
Richard Revelins (2)
|
77,343 | - | - | - | 73,928 | 151,270 | ||||||||||||||||||
Dianne Angus (1)
|
316,251 | - | 26,040 | 6,303 | - | 348,595 | ||||||||||||||||||
393,594 | - | 26,040 | 6,303 | 73,928 | 499,865 |
|
(1) Base Fee includes movements in annual leave provision for Ms
.
Dianne Angus accrued in accordance with his employment contract.
|
|
(2) Mr. Revelins received unlisted options during the year ended June 30, 2013. The option prices were calculated using the Black-Scholes Model applying the following inputs:
|
Grant Date: December 12, 2012
|
Volatility: 52.30%
|
Exercise Price: A$0.33
|
Risk-free Interest Rate: 2.73%
|
Stock Price: A$0.21
|
Dividend Yield: 0%
|
Years to Expiry: 5.00
|
Option Price: A$0.0739
|
Directors
|
Duration
|
Notice Requirements
|
Termination
|
|
Mr. Geoffrey Kempler
|
Until termination by either party
Signed September 21, 2007
|
For Good Reason Mr. Kempler may terminate with 30 days’ notice
Or
Without Cause the Company may terminate with 90 days’ notice
|
●
●
●
|
Pay Mr. Kempler within ninety (90) days of the termination date A$1,000,000 provided the Company has sufficient capital requirements to fulfill this clause
Accrued entitlements including all unreimbursed business expenses
Accelerate the vesting of any unvested options
|
Without Good Reason Mr. Kempler may terminate with 90 days’ notice
Or
With Cause the Company may terminate with 30 days’ notice
|
●
|
Bonus pro-rate only if termination occurs in 1
st
year
|
Key Management Personnel
|
Duration
|
Notice Requirements
|
Termination
|
|
Ms Dianne Angus
|
Until termination by either party
Signed October 2, 2006
Letter Agreement signed June 12, 2007
|
For Good Reason Ms
.
Angus may terminate with 30 days’ notice
Or
Without Cause the Company may terminate with 120 days’ notice
|
●
●
●
|
Pay remuneration entitlements three months from the time of termination (less any payout made for the notice period). The Company can elect to pay such sum as cash, equity in the Company or as a combination of both cash and equity
Accrued entitlements including all unreimbursed business expenses
Accelerate the vesting of any unvested options
|
Without Good Reason Ms Angus may terminate with 120 days’ notice
Or
With Cause the Company may terminate without notice
|
●
●
|
Permitted to keep and/or exercise options that have vested at the time of termination
Accrued entitlements including all unreimbursed business expenses
|
||
Ms Kathryn Andrews
|
Until termination by either party
Signed November 11, 2014
|
Ms Andrews may terminate with 30 days’ notice
Or
Without Cause the Company may terminate with 30 days notice
Or
With Cause the Company may terminate without notice
|
●
●
|
Permitted to keep and/or exercise options that have vested at the time of termination
Accrued entitlements including all unreimbursed business expenses
|
c. Key Management Personnel Equity Holdings
|
Fully Paid Ordinary Shares of the Company
|
Balance July 1, 2014
|
Received as Remuneration
|
Received on Exercise of Options
|
Net Change
Other (1)
|
Balance
June 30, 2015
|
|||||||||||||||
No.
|
No.
|
No.
|
No.
|
No.
|
||||||||||||||||
Geoffrey Kempler
|
17,811,000 | - | - | 200,000 | 18,011,000 | |||||||||||||||
Brian Meltzer
|
326,666 | - | - | - | 326,666 | |||||||||||||||
George Mihaly
|
226,666 | - | - | - | 226,666 | |||||||||||||||
Peter Marks
|
43,111 | - | - | - | 43,111 | |||||||||||||||
Lawrence Gozlan
|
- | - | - | - | - | |||||||||||||||
Ira Shoulson
|
- | - | - | - | - | |||||||||||||||
Richard Revelins (5)
|
20,308 | - | - | (20,308 | ) | - | ||||||||||||||
Dianne Angus
|
146,128 | - | - | - | 146,128 | |||||||||||||||
Phillip Hains (5)
|
211,800 | - | - | (211,800 | ) | - | ||||||||||||||
Kathryn Andrews (6)
|
- | - | - | - | - | |||||||||||||||
18,785,679 | - | - | (32,108 | ) | 18,753,571 |
Fully Paid Ordinary Shares of the Company
|
Balance July 1, 2013
|
Received as Remuneration
|
Received on Exercise of Options
|
Net Change Other (1)
|
Balance
June 30, 2014
|
|||||||||||||||
No.
|
No.
|
No.
|
No.
|
No.
|
||||||||||||||||
Geoffrey Kempler
|
17,811,000 | - | - | - | 17,811,000 | |||||||||||||||
Brian Meltzer
|
326,666 | - | - | - | 326,666 | |||||||||||||||
George Mihaly
|
226,666 | - | - | - | 226,666 | |||||||||||||||
Peter Marks
|
43,111 | - | - | - | 43,111 | |||||||||||||||
Lawrence Gozlan
|
- | - | - | - | - | |||||||||||||||
Ira Shoulson (3)
|
- | - | - | - | - | |||||||||||||||
Richard Revelins
|
20,308 | - | 500,000 | (500,000 | ) | 20,308 | ||||||||||||||
Dianne Angus
|
- | - | 868,547 | (722,419 | ) | 146,128 | ||||||||||||||
Phillip Hains (4)
|
211,800 | - | - | - | 211,800 | |||||||||||||||
18,639,551 | - | 1,368,547 | (1,222,419 | ) | 18,785,679 |
Fully Paid Ordinary Shares of the Company
|
Balance July 1, 2012
|
Received as Remuneration
|
Received on Exercise of Options
|
Net Change Other (1)
|
Balance
June 30, 2013
|
|||||||||||||||
No.
|
No.
|
No.
|
No.
|
No.
|
||||||||||||||||
Geoffrey Kempler
|
17,811,000 | - | - | - | 17,811,000 | |||||||||||||||
Brian Meltzer
|
326,666 | - | - | - | 326,666 | |||||||||||||||
George Mihaly
|
226,666 | - | - | - | 226,666 | |||||||||||||||
Peter Marks
|
43,111 | - | - | - | 43,111 | |||||||||||||||
Lawrence Gozlan (2)
|
- | - | - | - | - | |||||||||||||||
Richard Revelins
|
20,308 | - | - | - | 20,308 | |||||||||||||||
Dianne Angus
|
- | - | - | - | - | |||||||||||||||
18,427,751 | - | - | - | 18,427,751 |
|
|
Share Options of
the Company
|
Balance
July 1, 2014
No.
|
Granted as Remuneration
No.
|
Options Exercised
No.
|
Options Forfeited
No.
|
Net Change Other
|
Options Vested
During 2015 fiscal year
|
Balance
June 30, 2015
No.
|
Total Vested and Exercisable
June 30, 2015
No.
|
Total Unvested June 30, 2015
No.
|
|||||||||||||||||||||||||||
Geoffrey Kempler
|
4,000,000 | - | - | - | - | - | 4,000,000 | 4,000,000 | - | |||||||||||||||||||||||||||
Brian Meltzer
|
1,000,000 | - | - | - | - | - | 1,000,000 | 1,000,000 | - | |||||||||||||||||||||||||||
George Mihaly
|
1,000,000 | - | - | - | - | - | 1,000,000 | 1,000,000 | - | |||||||||||||||||||||||||||
Peter Marks
|
1,000,000 | - | - | - | - | - | 1,000,000 | 1,000,000 | - | |||||||||||||||||||||||||||
Lawrence Gozlan
|
1,000,000 | - | - | - | - | - | 1,000,000 | 1,000,000 | - | |||||||||||||||||||||||||||
Ira Shoulson
|
- | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||
Richard Revelins (5)
|
500,000 | - | - | - | (500,000 | ) | - | - | - | - | ||||||||||||||||||||||||||
Dianne Angus
|
317,819 | 1,000,000 | - | - | - | - | 1,317,819 | 1,317,819 | - | |||||||||||||||||||||||||||
Phillip Hains (5)
|
- | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||
Kathryn Andrews (6)
|
- | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||
8,817,819 | 1,000,000 | - | - | (500,000 | ) | - | 9,317,819 | 9,317,819 | - | |||||||||||||||||||||||||||
Share Options of
the Company
|
Balance
July 1, 2013
No.
|
Granted as Remuneration
No.
|
Options Exercised
No.
|
Options Forfeited
No.
|
Net Change Other (1)
|
Options Vested
During 2014 fiscal year
|
Balance
June 30, 2014
No.
|
Total Vested and Exercisable
June 30, 2014
No.
|
Total Unvested June 30, 2014
No.
|
|||||||||||||||||||||||||||
Geoffrey Kempler
|
4,000,000 | - | - | - | - | - | 4,000,000 | 4,000,000 | - | |||||||||||||||||||||||||||
Brian Meltzer
|
1,000,000 | - | - | - | - | - | 1,000,000 | 1,000,000 | - | |||||||||||||||||||||||||||
George Mihaly
|
1,000,000 | - | - | - | - | - | 1,000,000 | 1,000,000 | - | |||||||||||||||||||||||||||
Peter Marks
|
1,000,000 | - | - | - | - | - | 1,000,000 | 1,000,000 | - | |||||||||||||||||||||||||||
Lawrence Gozlan
|
1,000,000 | - | - | - | - | - | 1,000,000 | 1,000,000 | - | |||||||||||||||||||||||||||
Ira Shoulson (3)
|
- | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||
Richard Revelins
|
1,000,000 | - | (500,000 | ) | - | - | - | 500,000 | 500,000 | - | ||||||||||||||||||||||||||
Dianne Angus
|
2,052,730 | 160,000 | (868,547 | ) | - | (1,026,364 | ) | - | 317,819 | 317,819 | - | |||||||||||||||||||||||||
Phillip Hains (4)
|
- | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||
11,052,730 | 160,000 | (1,368,547 | ) | - | (1,026,364 | ) | - | 8,817,819 | 8,817,819 | - | ||||||||||||||||||||||||||
Share Options of
the Company
|
Balance
July 1, 2012
No.
|
Granted as Remuneration
No.
|
Options Exercised
No.
|
Options Forfeited
No.
|
Net Change Other (1)
|
Options Vested
During 2013 fiscal year
|
Balance
June 30, 2013
No.
|
Total Vested and Exercisable
June 30, 2013
No.
|
Total Unvested June 30, 2013
No.
|
|||||||||||||||||||||||||||
Geoffrey Kempler
|
- | 4,000,000 | - | - | - | - | 4,000,000 | 4,000,000 | - | |||||||||||||||||||||||||||
Brian Meltzer
|
- | 1,000,000 | - | - | - | - | 1,000,000 | 1,000,000 | - | |||||||||||||||||||||||||||
George Mihaly
|
- | 1,000,000 | - | - | - | - | 1,000,000 | 1,000,000 | - | |||||||||||||||||||||||||||
Peter Marks
|
- | 1,000,000 | - | - | - | - | 1,000,000 | 1,000,000 | - | |||||||||||||||||||||||||||
Lawrence Gozlan (2)
|
- | 1,000,000 | - | - | - | - | 1,000,000 | 1,000,000 | - | |||||||||||||||||||||||||||
Richard Revelins
|
- | 1,000,000 | - | - | - | - | 1,000,000 | 1,000,000 | - | |||||||||||||||||||||||||||
Dianne Angus
|
2,052,730 | - | - | - | - | - | 2,052,730 | 1,857,893 | 194,837 | |||||||||||||||||||||||||||
2,052,730 | 9,000,000 | - | - | - | - | 11,052,730 | 10,857,893 | 194,837 | ||||||||||||||||||||||||||||
|
(1) Net change other refers to shares purchased or sold during the financial year.
|
|
(2) Balance at date of appointment, August 8, 2011.
|
|
(3) Balance at date of appointment, May 13, 2014.
|
|
(4) Balance at date of appointment, May 1, 2014.
|
|
(5) Balance at date of retirement, November 4, 2014.
|
|
(6) Balance at date of appointment, November 4, 2014.
|
24.
|
SEGMENT INFORMATION
|
25.
|
FINANCIAL INSTRUMENTS
|
(a)
|
Market Risk
|
Consolidated Entity
|
||||||||
2015
|
2014
|
|||||||
A$
|
A$
|
|||||||
Cash and cash equivalents (USD)
|
27,100,354 | 26,398,943 | ||||||
Cash and cash equivalents (€EUR)
|
- | - | ||||||
Cash and cash equivalents (£GBP)
|
- | - | ||||||
Trade and other payables (USD)
|
(79,490 | ) | (37,934 | ) | ||||
Trade and other payables (€EUR)
|
(25,617 | ) | (36,168 | ) | ||||
Trade and other payables (£GBP)
|
(4,926 | ) | (205,649 | ) | ||||
Total exposure
|
26,990,321 | 26,119,192 |
·
|
A$98,442 in an Australian dollar transaction account at an interest rate of 0.05% as of June 2015;
|
·
|
A$2,507 in an Australian dollar transaction account at an interest rate of 0.00% as of June 2015;
|
·
|
A$1,707,493 in an Australian Business Cash High Interest account at an interest rate of 1.50% as of June 2015;
|
·
|
A$47 in an Australian Trust account at an interest rate of 0% as of June 2015;
|
·
|
US$20,750,646 (A$27,098,476) in U.S. checking accounts at an interest rate of 0.03% as of June 30, 2015;
|
·
|
A$6,000,000 in a three month term deposit at a fixed interest rate of 2.92% which matures on September 24, 2015;
|
·
|
A$152,603 in a six month term deposit at a fixed interest rate of 2.90% which matures on October 13, 2015;
|
·
|
A$45,462 in a twelve month term deposit at a fixed interest rate of 3.10% which matures on March 7, 2016;
|
·
|
A$500 in petty cash which does not earn any interest;
|
·
|
CAD$219 (A$231) in petty cash which does not earn any interest; and
|
·
|
US$1,438 (A$1,878) in petty cash which does not earn any interest.
|
·
|
A$154,747 in an Australian dollar transaction account at an interest rate of 0.05% as of June 2014;
|
·
|
A$2,612,870 in an Australian Business Cash High Interest account at an interest rate of 2.35% as of June 2014;
|
·
|
A$258 in an Australian Trust account at an interest rate of 0% as of June 2014;
|
·
|
US$24,881,751 (A$26,397,678) in U.S. checking accounts at an interest rate of 0.03% as of June 30, 2014;
|
·
|
A$5,000,000 in a three month term deposit at a fixed interest rate of 3.76% which matures on July 6, 2014;
|
·
|
A$43,988 in a twelve month term deposit at a fixed interest rate of 3.35% which matures on March 7, 2015;
|
·
|
A$200 in petty cash which does not earn any interest; and
|
·
|
US$1,192 (A$1,265) in petty cash which does not earn any interest.
|
June 30, 2015
|
Floating
Interest Rate
(A$)
|
Fixed Interest
Maturing in
(A$)
|
Non-Interest bearing
(A$)
|
Total
(A$)
|
Average Interest Rate
|
|||||||||||||||||||
1 year
or less
|
1-5 years
|
|||||||||||||||||||||||
Financial Assets
|
||||||||||||||||||||||||
Cash and cash equivalents
|
34,906,965 | - | - | 2,609 | 34,909,574 | 0.59 | % | |||||||||||||||||
Trade and other receivables
|
- | - | - | 6,521,154 | 6,521,154 | |||||||||||||||||||
Other current assets
|
- | 152,603 | - | 160,862 | 313,465 | 0.01 | % | |||||||||||||||||
Other non-current assets
|
- | - | 45,462 | - | 45,462 | 0.39 | % | |||||||||||||||||
Total Financial Assets
|
34,906,965 | 152,603 | 45,462 | 6,684,625 | 41,942,258 | |||||||||||||||||||
Financial Liabilities
|
||||||||||||||||||||||||
Trade and other payables
|
- | - | - | 2,152,015 | 2,152,015 | |||||||||||||||||||
Other financial liabilities
|
- | - | - | 12,076 | 12,076 | |||||||||||||||||||
Total Financial Liabilities
|
- | - | - | 2,164,091 | 2,164,091 |
June 30, 2014
|
Floating
Interest Rate
(A$)
|
Fixed Interest
Maturing in
(A$)
|
Non-Interest bearing
(A$)
|
Total
(A$)
|
Average Interest Rate
|
|||||||||||||||||||
1 year
or less
|
1-5 years
|
|||||||||||||||||||||||
Financial Assets
|
||||||||||||||||||||||||
Cash and cash equivalents
|
34,165,553 | - | - | 1,465 | 34,167,018 | 0.75 | % | |||||||||||||||||
Trade and other receivables
|
- | - | - | 7,285,409 | 7,285,409 | |||||||||||||||||||
Other current assets
|
- | - | 43,988 | - | 43,988 | 1.05 | % | |||||||||||||||||
Total Financial Assets
|
34,165,553 | - | 43,988 | 7,286,874 | 41,496,415 | |||||||||||||||||||
Financial Liabilities
|
||||||||||||||||||||||||
Payables
|
- | - | - | 3,358,358 | 3,358,358 | |||||||||||||||||||
Other financial liabilities
|
- | - | - | 98,398 | 98,398 | |||||||||||||||||||
Total Financial Liabilities
|
- | - | - | 3,456,756 | 3,456,756 |
Maturities of Financial Liabilities
|
||||||||||||||||||||
2015
|
Less than 6 months
|
6-12 months
|
Greater than 12 months and less than 5 years
|
Total contracted cash flows
|
Carrying amounts
|
|||||||||||||||
Consolidated Entity
|
||||||||||||||||||||
Trade and other payables
|
2,152,015 | - | - | 2,152,015 | 2,152,015 | |||||||||||||||
Total
|
2,152,015 | - | - | 2,152,015 | 2,152,015 | |||||||||||||||
2014
|
||||||||||||||||||||
Consolidated Entity
|
||||||||||||||||||||
Trade and other payables
|
3,358,358 | - | - | 3,358,358 | 3,358,358 | |||||||||||||||
Total
|
3,358,358 | - | - | 3,358,358 | 3,358,358 |
-
|
quoted prices in active markets for identical assets or liabilities (Level 1);
|
-
|
inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices) (Level 2); and
|
-
|
inputs for the asset or liability that are not based on observable market data (unobservable inputs) (Level 3).
|
26.
|
ADDITIONAL COMPANY INFORMATION
|
Registered
|
Office
Principal Place of Business
|
Suite 1
|
Level 2
|
1233 High Street
|
369 Royal Parade
|
Armadale Vic 3143
|
Parkville Vic 3052
|
Australia
|
Australia
|
Tel: +61 (03) 9824 5254
|
Tel: +61 (03) 9349 4906
|
Prana Biotechnology Limited
|
|||
|
By:
|
/s/ Geoffrey P. Kempler | |
Geoffrey P. Kempler
|
|||
Chief Executive Officer
|
|||
SIXTH RESEARCH FUNDING AND INTELLECTUAL PROPERTY
|
ASSIGNMENT AGREEMENT
|
THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH
|
(ABN 92 124 762 027) of 30 Royal Parade, Parkville Victoria 3010 (“
Florey
”)
|
AND
|
PRANA
BIOTECHNOLOGY
LTD
(ABN 37 080 699 065) having its principal office at
|
Level 2, 369 Royal Parade, Parkville, Victoria, 3025 ("
Prana
")
|
INTRODUCTION
|
NOW IT IS AGREED:
|
1.
|
DEFINITIONS AND INTERPRETATION
|
1.1.
|
Definitions
|
(a)
|
information which is already in the public domain;
|
|
(b)
|
information which hereafter becomes part of the public domain otherwise than as a result of an unauthorised disclosure by the recipient Party or its representatives;
|
|
(c)
|
information which is or becomes available to the recipient Party from a third party lawfully in possession of such information and who has the lawful power to disclose such information to the recipient Party on a non-confidential basis;
|
|
(d)
|
information which is rightfully known by the recipient Party (as shown by its written record) prior to the date of disclosure to it hereunder; or
|
|
(e)
|
information which is independently developed by an employee of the recipient Party who has no knowledge of the disclosure under this Agreement.
|
|
(a)
|
where the Technology is a product, to make, hire, sell or otherwise dispose of that product, offer to make, sell, hire or otherwise dispose of it, use or import it, or keep it for the purpose of doing any of those things; or
|
|
(b)
|
where the Technology is know-how, a method or process, to use that know-how, method or process or do any act mentioned in paragraph (a) in respect of a product resulting from such use.
|
|
(a)
|
from 7 May 1999 to 31 December, 2013 which is identified in Schedules 1 – 5;
|
|
(b)
|
after 1 January, 2014 by the Parties which is identified in Schedule 6 or which is otherwise agreed from time to time by the Parties and identified in further schedule(s) to this Agreement.
|
|
(a)
|
Research Funding and Intellectual Property Assignment Agreement dated 1 December, 2000 (as amended by an Amending Agreement made on or about 5 August, 2002, a letter from Prana to the University dated 7 March, 2003 , the Third Research Funding and Intellectual Property Assignment Agreement referred to in paragraph (c) below and the Fifth Research Funding and Intellectual Property Assignment Agreement referred to in paragraph (e) below) in relation to Research conducted by the University and MHRI (as a subcontractor) for Prana in the period from 7 May, 1999 to 1 December, 2003;
|
|
(b)
|
undated Second Research Funding and Intellectual Property Assignment Agreement made on or about 1 October, 2004 in relation to Research conducted by the University and MHRI (as a subcontractor) for Prana in the period from 2 December, 2003 to 1 December, 2006;
|
|
(c)
|
Third Research Funding and Intellectual Property Agreement dated 29 June, 2007 (as amended by a letter agreement between the University and Prana made 2 May, 2008 and a letter agreement between the University and Prana dated 23 January, 2009) in relation to Research conducted by the University and MHRI (as a subcontractor) for Prana in the period from 2 December, 2006 to 1 December, 2009;
|
|
(d)
|
undated Fourth Research Funding and Intellectual Property Assignment Agreement in relation to Research conducted by the University and MHRI (as a subcontractor) for Prana in the period from 2 December, 2009 to 1 December, 2012;
|
|
(e)
|
undated Fifth Research Funding and Intellectual Property Assignment Agreement made on or about 2 August, 2013 in relation to Research conducted by the University and MHRI (as subcontractor) and/or Florey for Prana in the period from 1 December, 2012 to 31 December, 2013 (as amended in or about June 2013 to increase the budget for the Research from $512,917 to $545.000).
|
1.2
|
In this Agreement, except where the context indicates to the contrary:
|
|
(a)
|
the expression "person" includes an individual, a body corporate, a joint venture, a trust, an agency or other body;
|
|
(b)
|
words importing the singular will include the plural (and vice versa) and words denoting a given gender will include all other genders;
|
|
(c)
|
headings are for convenience only and will not affect interpretation of this Agreement;
|
(d)
|
all monetary amounts will be deemed to be in Australian currency; and
|
|
(e)
|
references to any legislation or to any provision of any legislation will include any modification or re-enactment of such legislation or any legislative provision substituted for and all legislation and statutory instruments issued under such legislation.
|
2.
|
TERM
|
2.1
|
This Agreement will begin on the Effective Date and will continue for the period during which any Intellectual Property Rights subsist in the Technology in any jurisdiction, subject to earlier termination in accordance with this Agreement.
|
2.2
|
The Research began on 7 May 1999 and will continue for as long as the Parties agree to Research being conducted pursuant to this Agreement, it being agreed that:
|
|
(a)
|
each body of agreed Research and the funding, timing and relevant operational matters relevant thereto will be recorded in a Schedule which shall form part of this Agreement;
|
|
(b)
|
such Research may be terminated by Prana in accordance with clause 19.3.
|
3.
|
FUNDS
|
3.1
|
Prana will pay Florey the Funds as specified in each Schedule. The Parties acknowledge and agree that there are no outstanding Funds payable by Prana in relation to the Research referred to in Schedules 1 – 5.
|
3.2
|
Florey will apply the Funds solely to the carrying out of the Research in accordance with the Research Plans to be developed by the Management Committee.
|
3.3
|
Without limiting the operation of clause 3.2, Funds can only be applied towards Research carried out at Florey or by Florey affiliated staff members.
|
3.4
|
The Parties will ensure that:
|
(a)
|
proper accounting standards and controls are exercised in respect of the Funds; and
|
|
(b)
|
income and expenditure in relation to the Research are recorded separately from other transactions of the Parties.
|
3.5
|
Florey will establish an Account for the purposes of the Research.
|
3.6
|
Florey will ensure that:
|
|
(a)
|
any moneys forming part of the Funds are deposited in the Account;
|
|
(b)
|
all drawings on the Account during the Term are applied solely to the carrying out of the Research and not for any other purpose; and
|
|
(c)
|
any interest on the balance of the Account is credited to the Account.
|
4.
|
MANAGEMENT AND ADMINISTRATION
|
5.
|
MANAGEMENT COMMITTEE
|
5.1
|
The Parties must establish the Management Committee, which will be comprised of:
|
|
(a)
|
Representatives nominated by Florey; and
|
|
(b)
|
Representatives nominated by Prana,
|
5.2
|
The Project Manager must be nominated by his or her employing Party to be one of that Party's Representatives on the Management Committee.
|
5.3
|
Each member of the Management Committee (including the Project Manager) may delegate his/her powers and responsibilities as a member of the Management Committee to another person provided they provide the other Party with reasonable written prior notice.
|
5.4
|
Meetings of the Management Committee will be chaired by the Project Manager (or the Project Manager's delegate).
|
5.5
|
The quorum for a meeting of the Management Committee is all four (4) members (or their delegates) and the quorum must be present at all times during the meeting. If a quorum is not present at a meeting of the Management Committee within thirty (30) minutes after the scheduled time for the meeting, the members of the Management Committee who are present at the meeting will agree upon a date, time and place to which the meeting is adjourned.
|
5.6
|
All decisions of the Management Committee must be resolved by unanimous agreement of all members (or their delegates) of the Management Committee. All members (or their delegates) of the Management Committee will have equal voting powers at meetings of the Management Committee.
|
5.7
|
Decisions of the Management Committee on any matter shall be by way of resolution and shall be recorded in minutes of Management Committee meetings or by correspondence signed by all members (or their delegates) to be kept by the Project Manager.
|
5.8
|
Each Party will bear its own costs in respect of its participation on the Management Committee.
|
6.
|
MANAGEMENT COMMITTEE RESPONSIBILITIES
|
6.1
|
The Management Committee's responsibilities will be as follows:
|
|
(a)
|
to meet and determine the Research Plan for the following year;
|
|
(b)
|
to monitor the progress of Research undertaken by Florey;
|
|
(c)
|
to determine the Budget for each year in accordance with this Agreement;
|
|
(d)
|
to make and implement management decisions relating to the conduct of the Research, provided that such decisions are consistent with this Agreement and the Research Plan;
|
|
(e)
|
to discuss the Interim Reports and progress of the Research in general; and
|
|
(f)
|
to define and agree upon proposed modifications of or extensions to the Research, provided however that the Research will only be amended if each Party has approved such amendment.
|
7.
|
PROJECT MANAGER
|
7.1
|
The Parties hereby appoint as Project Manager the person identified as such in the then current Schedule.
|
7.2
|
The Project Manager will:
|
|
(a)
|
be responsible for the day to day management of the Research;
|
|
(b)
|
ensure that the Research is carried out in accordance with the Research Plan and within the Budget; and
|
|
(c)
|
report to the Management Committee as and when required by this Agreement and at other times as requested by the Management Committee.
|
7.3
|
The Project Manager may be replaced at any time by the mutual agreement of the Parties.
|
8.
|
RESEARCH PLAN FOR EACH YEAR
|
8.1
|
By each anniversary of the Effective Date prior to the relevant year, the Management Committee will draft and finalise for that year the Research Plan and Budget for that year, including:
|
|
(a)
|
a list of all Research Projects; and
|
|
(b)
|
details of each Research Project to be conducted by Florey during the relevant year, including:
|
9.
|
CONDUCT OF RESEARCH
|
9.1
|
Florey will ensure that the Research is carried out in a diligent and competent fashion, consistent with generally accepted professional, scientific and ethical standards of conduct.
|
9.2
|
The Research Plan may not be varied except with the unanimous agreement in writing of all the Parties.
|
10.
|
REPORTING
|
10.1
|
The Project Manager will submit to the Management Committee within fourteen (14) days of the end of each quarter of each calendar year during the Term of this Agreement an Interim Report detailing Florey's progress against the milestones for each Research Project specified in the Research Plan for that year.
|
10.2
|
Each Interim Report will summarise the work completed on the Research Plan up to the date of such Interim Report, the work anticipated over the next reporting period, and will identify problems which may cause or are causing a deviation from the Research Plan and the steps, if any, being taken or proposed to be taken to alleviate such problems.
|
10.3
|
Within sixty (60) days of the completion of the Research Plan, Florey will provide the Management Committee with the Final Report describing the results of the Research Plan, including activities undertaken, difficulties encountered and achievements made (including any Project Technology).
|
11
|
RIGHTS TO PROJECT TECHNOLOGY
|
11.1
|
Subject to this clause 11, all rights (including Intellectual Property Rights) to the University Background Technology will remain vested solely in the University.
|
11.2
|
Subject to this clause 11, all rights (including Intellectual Property Rights) to Prana Background Technology will remain vested solely in Prana.
|
11.3
|
Prana hereby grants Florey a royalty free, non-exclusive right to use Prana Background Technology and Project Technology to the extent that it is necessary for the carrying out of the Research and for internal teaching and research.
|
11.4
|
The Parties agree that ownership of the Project Technology and all Intellectual Property Rights subsisting therein will vest exclusively in Prana. Prana will decide which of the Project Technology will be:
|
|
(a)
|
retained as Confidential Information; or
|
|
(b)
|
included in any patent application or other application for registered Intellectual Property Rights protection.
|
11.5
|
Upon determination by Prana that the Project Technology will be included in any patent application or other application for registered Intellectual Property Rights protection, such application will be made by Prana in its name and Florey will render all assistance that Prana may reasonably require in the prosecution of that application.
|
11.6
|
Applications for registration pursuant to clause 11.5 and the maintenance of subsequent registrations (as the case may be) will be the responsibility of Prana. Registration Costs will be met by Prana. If Prana fails to meet Registration Costs in respect of any application, the rights granted to it under this clause 11 will lapse and Florey will at its option be entitled to continue to meet such Registration Costs, in which case all Intellectual Property Rights in the subject matter of those applications and subsequent registrations (as the case may be) are assigned (by way of assignment of future Intellectual Property Rights) to Florey, and Prana will have no rights in respect of the same.
|
11.7
|
Florey undertakes to notify the terms of this Agreement as they relate to ownership of, and rights to, the Project Technology and the Intellectual Property Rights subsisting therein, to all employees and subcontractors (if any) conducting Research under this Agreement.
|
11.8
|
Prana grants to Florey a non-exclusive royalty free, worldwide, perpetual and irrevocable licence to Exploit the Technology for the duration of the period in which Intellectual Property Rights subsist in the Technology, either itself or with other academic institutions provided only that such Exploitation is restricted to Florey's educational purposes in delivering education programs, including, without limitation, Florey's research, teaching and scholastic endeavours.
|
12
|
ROYALTIES
|
12.1
|
Prana shall pay to Florey the following amounts:
|
|
(a)
|
royalties calculated at 1.5% of the Net Invoice Price of all Products sold by or on behalf of Prana or any agent, contractor or Affiliate of Prana; or
|
|
(b)
|
the lesser of:
|
|
(i)
|
1.5% (subject to any reduction under clause 12.3) of the Net Invoice Price of Products sold by or on behalf of; or
|
|
(ii)
|
10% of the gross revenues (including royalties and any other payments) relating to Exploitation of Project Technology receivable from,
|
12.2
|
The amounts payable in clause 12.1(a) and (b) must be paid each six months, within two months following the end of each December and June. All payments must be accompanied by a statement setting out the manner in which the payment has been calculated which includes for Prana and each licensee or assignee of Prana:
|
|
(a)
|
the subject matter to which the payment relates;
|
|
(b)
|
the number of Products sold, the gross revenues received or the nature of the rights granted in relation to the Technology and the identity of the licensee and/or assignee as the case may be;
|
|
(c)
|
the gross amounts payable in relation to the sale or sales in (b) by the purchaser, licensee, sublicensee, and/or assignee;
|
|
(d)
|
the nature and amount of deductions made from the gross amount in (c); and
|
|
(e)
|
such other information as Florey may reasonably require from time to time.
|
12.3
|
Where the exploitation of any Product which attracts a payment pursuant to the preceding provisions of this clause 12, (other than clause 12.1(b)(ii)) also attracts a genuine good faith obligation to pay a royalty or percentage of such payment to any third party (which is not an agent, contractor or Affiliate of Prana), then the percentage of the payment required to be paid by Prana to Florey will be varied in accordance with the following provision.
|
12.4
|
Where Exploitation of the Technology (including Exploitation of a Product) is not undertaken at arm's length, the price or value of the Exploitation (including the price of a Product) for the purposes of calculation of payments under clause 12.1 will be deemed to be the amount which would have been payable had the transaction been negotiated in good faith between the parties at arm's length.
|
12.5
|
Prana must keep true and accurate records of all matters connected with the Exploitation of the Technology and must also keep proper books of account relating to the calculation of payments to Florey under this Agreement. On Florey's written request, Prana must produce these records and books of account, certified as correct by Prana's auditors, and must permit those records and books to be examined by or on behalf of Florey. Florey may conduct such an examination up to once each calendar year and will do so at its own cost, unless the examination identifies a deviation equal to or greater than 10% in the amounts identified as payable to Florey, in which case the costs are to be paid by Prana.
|
12.6
|
Prana must at all times use its best endeavours to Exploit the Technology in such a way that maximises the payments to be made to Florey pursuant to this Agreement. Prana must provide to Florey such information as Florey may reasonably request concerning Prana's plans for, and efforts in, exploiting the Assigned IP and Project Technology. Prana must not engage in any activity that conflicts with its obligation under this clause.
|
12.7
|
In determining whether Prana has used its best endeavours regard will be had to the achievements or failure of Prana to meet the Minimum Performance Levels.
|
12.8
|
If Prana's payments under clause 12.I do not meet or exceed the Minimum Performance Levels, Prana must pay to Florey the difference between the Minimum Performance Levels and the amounts actually paid.
|
13
|
CONFIDENTIALITY
|
13.1
|
Each Party will treat the terms of this Agreement and all Confidential Information of the other Party as confidential and will not, without the prior written consent of the other Party, disclose or permit the same to be disclosed to any third person.
|
13.2
|
It will be the responsibility of a Party to ensure that its employees, officers and agents comply with the obligations of confidentiality imposed upon it by this clause 13 as if personally bound by such obligations.
|
13.3
|
Each Party's obligations under this clause 13 will survive termination of this Agreement and endure until the Confidential Information disclosed to it lawfully becomes part of the public domain.
|
14
|
PUBLICATIONS AND MARKINGS
|
14.1
|
Prana must not use the name or logo of Florey without having obtained Florey's prior written consent and the use of Florey's name or logo will be subject to any conditions attaching to such consent.
|
14.2
|
Prana must not make or permit to be made any inaccurate or misleading statement concerning Florey.
|
14.3
|
Subject to paragraph (b), Florey may not publish results of the Research, without the consent of Prana. If Florey requests that Prana consent to a publication, Prana may not withhold that consent unless in its reasonable view the publication includes Confidential Information of Prana and the publication would adversely affect protection or Exploitation of the Project Technology. If Florey makes such a request and receives no response from Prana within 90 days, Prana will be deemed to have consented to the proposed publication.
|
14.4
|
Florey may make a publication which is constituted by the presentation of a thesis by a Florey student, provided that appropriate steps are taken to ensure that confidentiality of information contained in the thesis is maintained, including the examiner signing an appropriate confidentiality undertaking and the placing of an appropriate access limitation on the thesis where it is required to be placed in a Florey library.
|
15.
|
INSURANCE
|
15.1
|
Prana will:
|
|
(a)
|
Exploit the Technology at its own risk; and
|
|
(b)
|
maintain or cause to be maintained adequate professional indemnity, product liability and third party liability insurance in respect of Exploitation of the Technology.
|
15.2
|
Prana will, upon the request of Florey, produce evidence of the currency of the insurance policies referred to in this clause 15. Failure by Prana to produce such evidence of currency within thirty (30) days from the date a notice of request is served upon Prana will be treated as breach by Prana of this clause 15 and the relevant provisions of clause 19 will apply.
|
15.3
|
Prana undertakes at all times to comply with the terms of its insurance policies the subject of clause 15.1.
|
15.4
|
Prana's obligations under this clause 15 will survive expiration or earlier termination of this Agreement.
|
16.
|
ACKNOWLEDGEMENT BY PRANA
|
16.1
|
Prana hereby agrees and acknowledges that:
|
|
(a)
|
Florey has not made any and hereby excludes all warranties, terms, conditions or undertakings, whether express or implied, written or oral, statutory or otherwise including any implied warranty of merchantability or of fitness for a particular purpose in respect of the Research or the Technology. To the full extent permitted by the laws of the Commonwealth of Australia or of any State or Territory of Australia having jurisdiction, any conditions or warranties imposed by such legislation are hereby excluded. In so far as liability under or pursuant to such legislation may not be excluded, such liability is limited, at the exclusive option of Florey, to:
|
|
(b)
|
without limiting the generality of clause 16.1(a) it is agreed that, to the full extent permitted by the laws of the Commonwealth of Australia and any State or Territory of Australia having jurisdiction, Florey will not be liable for any special, indirect or consequential damages arising under or pursuant to this Agreement.
|
16.2
|
Without limiting the generality of clause 16.1, Prana hereby further acknowledges and agrees that:
|
|
(a)
|
Prana will be responsible for obtaining any approvals, authorisations and accreditations necessary or desirable to enable it to use or Exploit the Technology;
|
|
(b)
|
while Florey may discuss with Prana requirements for obtaining any approvals, authorisations and accreditations necessary or desirable to enable Prana to use or Exploit the Technology, Florey has not made and does not by entering into this Agreement make any representations or give any warranties regarding the suitability of the Technology for such purposes;
|
|
(c)
|
if any Commonwealth or State taxes by duties (including stamp duty) are payable in respect of this Agreement, the payment of same will be the responsibility of Prana;
|
|
(d)
|
Florey has not made and does not by entering into this Agreement make any representations or give any warranties that this Agreement or the Research is structured so as to entitle Prana to obtain any form of taxation relief or concession under the
Income Tax Assessment Act 1936
(Cth), (whether pursuant to section 73B of that Act or otherwise) or under any other Commonwealth or State legislation. Prana agrees that it will be responsible for making its own inquiries with respect to these matters;
|
|
(e)
|
Florey has not made and does not by entering into this Agreement make any representation or warranty, express or implied, that the Technology do not infringe any third party's Intellectual Property Rights.
|
16.3
|
This clause l6 will survive expiration or, where relevant, earlier termination of this Agreement.
|
17.
|
INDEMNITIES AND WARRANTIES
|
17.1
|
Prana hereby releases and indemnifies and will continue to release and indemnify Florey, its officers, employees and agents from and against all actions, claims, proceedings or demands (including those brought by third parties) which may be brought against it or them, whether on their own or jointly with Prana and whether at common law, in equity or pursuant to statute or otherwise, in respect of any loss, death, injury, illness or damage (whether personal or property, and whether direct or consequential, including consequential financial loss) and any infringement of copyright, patents, trademarks, designs or other Intellectual Property Rights, howsoever arising out of Prana's exercise of its rights under this Agreement or Exploitation of any Project Technology and from and against all damages, costs and expenses incurred in defending or settling any such claim, proceeding or demand; except to the extent that any such liability may arise from the negligent or fraudulent acts or omissions of Florey.
|
17.2
|
Prana's obligation to indemnify Florey and its officers, employees and agents set out in clause 17.1 is a continuing obligation separate and independent of Prana's other obligations and will survive expiration or where relevant, earlier termination of this Agreement.
|
18.
|
INFRINGEMENT AND THIRD PARTY PROCEEDINGS
|
18.1
|
Each Party will give the other notice of:
|
|
(a)
|
any claim or allegation that the exercise of the rights under this Agreement constitute an infringement of the rights of any third party; and
|
|
(b)
|
any third party's infringement or threatened infringement of any of the Parties' Intellectual Property;
|
18.2
|
If Prana decides to commence legal proceedings, Florey will, at Prana's cost, furnish to Prana all reasonably necessary assistance in relation to those proceedings.
|
18.3
|
The terms and conditions of this clause 18 will survive expiration or earlier termination of this Agreement.
|
19.
|
TERMINATION
|
19.1
|
Either Party may terminate this Agreement or the Research and the rights and obligations of the Parties relating to conduct of the Research by providing the other Party with written notice on the happening of any of the following events:
|
|
(a)
|
if the other Party commits or allows to be committed a breach of any of the material obligations under this Agreement and on its part to be performed or observed, and does not within thirty (30) days of receipt of notice in writing from the first Party make good the breach (where such breach is capable of remedy);
|
|
(b)
|
if the other Party is the subject of winding up or liquidation proceedings, whether voluntary or compulsory, otherwise than for the purpose of and followed by, a reconstruction, amalgamation or reorganisation;
|
|
(c)
|
if the other Party has become insolvent, bankrupt or is subject to the appointment of a mortgagee, a receiver or manager or an inspector to investigate its affairs, enters into any arrangement or composition with its creditors generally, or is unable to pay its debts as and when they become due;
|
|
(d)
|
if execution is levied upon all or any part of the assets of the other Party, provided that no breach will take place hereunder if the execution is contested in good faith or if within seven (7) days after it is levied payment is made in full to the judgment creditor m question of all amounts owing to such judgment creditor;
|
19.2
|
Termination of this Agreement:
|
|
(a)
|
will be without prejudice to the rights of the terminating Party to sue for and recover any fees, monies, or payments then due and to the rights of the terminating Party in respect of any previous breach of any of the provisions of this Agreement; and
|
|
(b)
|
will not relieve either Party of their respective obligations of confidentiality, insurance and indemnity contained herein; and
|
|
(c)
|
by Florey does not relieve Prana of its payment obligations under clause 12, which shall continue for the period during which any Intellectual Property Rights subsist in the Technology in any jurisdiction.
|
19.3
|
Prana may terminate this Agreement and/or any Research without cause by giving one month written notice to Florey and such notice shall be effective one month from the date of receipt of the written notice by Florey.
|
19.4
|
This clause 19 will survive expiration or earlier termination of this Agreement.
|
20.
|
RESOLUTION OF DISPUTES
|
21.
|
NOTICES
|
21.1
|
Any notice, demand or other communication required to be given or made in writing tinder this Agreement will be deemed duly given or made if delivered or sent by prepaid post or facsimile transmission as follows:
|
|
(a)
|
in the case of Florey:
|
Attention:
|
Henry De Aizpurua
|
Address:
|
Florey of 30 Royal Parade, Parkville Victoria 3010
|
Facsimile:
|
(
613) 90353107
|
|
(b)
|
in the case of Prana:
|
Attention:
|
Geoffrey Kempler
|
Address:
|
Level 2, 369 Royal Parade, Parkville,
|
Victoria 3025 Australia
|
|
Facsimile:
|
(613) 9348 0377
|
21.2
|
Either Party may change its nominated contact person, address or facsimile transmission number for the purposes of this Agreement by giving notice of such change to the other Party within fourteen (14) days of the change.
|
21.3
|
Any notice or other communication will be deemed to have been received by the Party to which it was sent:
|
|
(a)
|
in the case of hand delivery, upon the date of such delivery;
|
|
(b)
|
in the case of prepaid post within Australia, on the third day next following the date of dispatch; or
|
|
(c)
|
in the case of facsimile transmission, at the time of transmission, provided that, following the transmission, the sender receives a transmission confirmation report unless in any such case it would be deemed to have been received on a day which is not a business day, or after 5 p.m. on such a business day, in which event it will be deemed to have been received on the next such business day.
|
22.
|
ANCILLARY PROVISIONS
|
22.1
|
Governing Law
|
22.2
|
Severability
|
22.3
|
Waiver
|
22.4
|
Amendment, Assignment and Subcontracting
|
22.5
|
Entire Agreement
|
22.6
|
Relationship
|
22.7
|
Force Majeure
|
22.8
|
Goods and Services Tax ('GST')
|
|
(a)
|
If, by operation of the GST Law, any Supply under this Agreement is regarded as a taxable supply, the Supplier will be entitled to recover from the Recipient, an amount equivalent to the GST payable by the Supplier in relation to the Supply, less any decrease in the cost to the Supplier of making the Supply resulting from the abolition or variation of any taxes, duties or statutory charges in relation to the imposition of GST.
|
|
(b)
|
If GST is payable, the Supplier will provide the Recipient with a tax invoice or a document adequate to entitle the Recipient to claim an input tax credit.
|
|
(c)
|
In this clause:
|
|
1.
|
Title:
|
A method of assaying and treating Alzheimer’s Disease
|
|
2.
|
Title:
|
The University’s rights in the invention entitled “Use of clioquinol for the prevention and
therapy of Alzheimer’s disease”.
|
1.
|
Studying the
Aβ
amyloid in the human and animal brain
|
2.
|
Evaluating the effect of
Aβ
on tissues, cells and in biochemical assays
|
3.
|
Assays of
Aβ
in experimental and natural systems
|
4.
|
Preparation of reagents necessary for the conduct of assays and experiments on
Aβ.
|
5.
|
Conduct of clinical trials in humans arising out of the Research.
|
Prana Biotechnology Ltd
By: ______________________________
Name:
Dianne Angus
Title:
Chief Operating Officer
Date: ____________________________
|
Certara LP-Sucursal em Portugal
By:_____________________________
Name: ______________________________
Title: ______________________________
Date: ______________________________
|
Prana Biotechnology Ltd
By:_____________________________
Name: ______________________________
Title: ______________________________
Date: ______________________________
|
|
1)
|
This Statement of Work made on [insert date] (the “SOW Date”) is entered into pursuant to the terms and conditions of the Master Services Agreement between the Parties dated [insert execution date of MSA].
|
/s/
Geoffrey P. Kempler
*
Geoffrey P. Kempler
Chief Executive Officer
|
/s/
Kathryn Andrews
*
Kathryn Andrews
Chief Financial Officer
|
/s/
Geoffrey P. Kempler
*
Geoffrey P. Kempler
Chief Executive Officer
|
/s/
Kathryn Andrews
*
Kathryn Andrews
Chief Financial Officer
|